ࡱ> '` bjbj{P{P .::  OOO8P,:Ql (4QXR4RRRSVRUdU4$\h9 XSSXX RRh{c{c{cXN R R{cX{c{cmL J RQ pЩ;OU_n=^o0(JHaZHH U|Vh{cVT8WUUUc^UUU(XXXX d 1 1   Website communication: Automatic mails 06/11/09 Adaptation of automatic mail velocity templates body text This document provides further information on the automatic mails sent by the FAMHP internal IT system during procedures for Marketing Authorisation applications (new and variations). Below, all automatic mails are listed and extra information on their interpretation is provided. Please note that soon, the system will be adapted in order to be able to accept grouped variations, annual reportings and worksharing (in line with Commission Regulation 1234/2008.). Due to this change to the system, technical features from existing and new workflows need to be adapted. If you note that the detailed dossier characteristics on the automatic mails is not correct, please contact our call center, so the error can be analysed. 1.Dossier receipt confirmation OK General information: This mail is sent by the FAMHP once the submitted dossiers has been uploaded in the system and passed the full compliance requirements (foreseen link to road map). This mail can be used as proof of implementation in case of national type IA/IB variations, MRP CMS type IA/IB variations and MRP CMS type II variations. Specific points of attention: All national and MRP CMS type IA variations received from 01.01.2010 can be implemented before submission. However, their implementation should be stopped immediately after reception of a negative advice of the competent authorities. Immediately will be explained later once experience is gained. All national and MRP CMS type IB variations (stand alone or part of grouped variations for which the highest ranking variation is a type IB variation) received from 01.01.2010 can be implemented: immediately upon reception of the approval of the competent authority or within 30 days after validation if no comments were sent by the competent authority. Within 6 months after the approval of the variation, the MAH ensures that the changes are implemented for the medicinal product batches that are released for the market. Both type IB variations as listed in the Commission Classification Guideline and the default type IB variations are concerned here. All MRP CMS type II variations received from 01.01.2010 can be implemented 30 days after reception of the approval of the competent authority on condition that  HYPERLINK "http://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.doc" all national documents needed to close the dossier have been sent to the FAMHP. In view of this implementation the MAH is obliged to use an SmPC which is the exact translation of the final SmPC and a PIL/labeling which are the exact translations of the harmonized PIL/labeling. Within 6 months after the approval of the variation, the MAH ensures that the changes are implemented for the medicinal product batches that are released for the market It is noted that for variations received before 01.01.2010, the implementation of a type II analytical variation following the MRP procedure when BE is CMS could be immediately after reception of the approval of the RMS. The time period within which the authorities should provide the outcome for type IA or type IB variations depends on the way of submission of the type IA/IB variation: for stand alone type IA/IB variations and grouped variations only including type IA and/or IB variations the advice should be given within 30 days. If the type IA/IB variation is part of grouped variations including a type II variation, the timetable of the type II variation will determine the time period for providing the advice on all variations within the group, e.g. if a grouped variation containing a type II variation with extended timetable (90 days) and a type IA variation is submitted, the authorities need to provide their advice on both variations within 90 days. If the type IA/IB variation is submitted within a group containing a line-extension, the advice is to be given within 90 days in case of an MRP line-extension, and within 210 days in case of a DCP line extension. In case a national grouped variation is submitted containing a type IB, variation, a type II variation and a line-extension, the submitted group will follow the timetable of the line-extensio,. If questions are raised the implementation of the type IB variation can be started once the authorities sent their approval of the variation group (this is the Round Up mail in case of national applications).The implementation of the type II variation can be started 30 calendar days after the approval (this is 30 days after the Round Up mail for national applications). The implementation of the line-extension can only be started once the MA Form is received by the applicant. In the mail it is mentioned that implementation of variations following the rules as determined in this mail is allowed on condition that no additional marketing authorisation is needed. (Only additional Marketing authorisation is concerned here. In case only the update of an existing marketing autjorisation is concerned the implementation rules mentioned in the mail are valid.) The variations for which a new marketing authorisation is to be awaited before implementation can be started are (the example are valid for parenteralia, but are not always applicable to other dosage forms): - Change in concentration of a single dose total use parenteral product where the amount of active substance per unit dose remains the same.(annex better regulation: II2 a) 5) - Change in immediate packaging of the finished product (annex better regulation: Nr II 2 e) 1) - Change in pack size of the FP if applicable (annex better regulation Nr II 2e) 5) (for further details see circular letter 439) The response times as mentioned in the automatic mail include both validation period and timetable. For type IB variations the validation is 7 days, and may be extended by 7 days in case of unforeseen type IB variations. .For type II variations the validation period is always 14 days. For each dossier submitted as default type IB variation, the FAMHP will ask the advice of the CMDh following art 5 of Commission Regulation EC/2008/1234, except if the applicant has asked the advice of the CMDh before submission and includes a copy of the CMDh advice when submitting the default type IB variation. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. We confirm that the Registration Dossier with the following characteristics is correctly received: Submission characteristics: - Entry date: $entrydate - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Procedure Type: $ProcedureType - Procedure Role: $ProcedureRole - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. $Note If your dossier concerns an administrative variation or a national procedure, variation type IA (stand alone or grouped), please stop the implementation of the variation immediately if you receive a negative advice from the FAMHP within datum $EntryDatestr + 30/44/74/104/224(*) calendar days. If your Dossier concerns a National Procedure, variation type IB (stand alone or grouped), please start the implementation of the variation within 6 months if you dont receive any comments from the FAMHP within $EntryDatestr + 44/74/104/224 (*) calendar days. If you receive comments, you have 30 calendar days to send your answers to the following address  HYPERLINK "mailto:varana@fagg-afmps.be" varana@fagg-afmps.be. If you do not receive a negative advise within 30 calendar days after the date of the introduction of your answers, the variation may be implemented if a national stand alone type IB variation is concerned, or if the highest ranking variation within the group is a type IB variation. If the highest ranking variation within the Group is a type II variation or a line-extension, the date of the Round Up mail can be considered as start date of the implementation period of the national type IB variation. !The above mentioned response times are only valid (1) in case the submitted national type IB variation is listed in the Commission Classification Guideline or (2) in case the applicant has called for article 5 of Commission Regulation EC/2008/1234 (**) and the variation has been classified as type IB variation. If this is not the case, and the national type IB variation is considered to be an unforeseen type IB variation, the FAMHP reserves the right to ask the advice of the CMDh. If your dossier concerns a mutual recognition procedure, variation IA/IB (stand alone or grouped), for which Belgium acts as CMS, please consider the date of receipt of the approval of the RMS as start date of the implementation period in case of a variation of type IB. Please stop the implementation of the variation of type IA immediately after receipt of the negative advice of the RMS. If your dossier concerns a mutual recognition procedure, variation type II (stand alone or grouped), for which Belgium acts as CMS, please consider the date of receipt of the approval of the RMS + 30 calendar days as start date of the implementation period. ! It is important to note that the implementation of the above mentioned variations based on this mail, is only valid in case the approved variation does not require an additional marketing authorization (MA). If an additional MA is required, you need to wait for the receipt of this MA before implementing the approved variation. For any other type of dossiers: We will start validating the registration dossier. We will contact you if there are any problems regarding the validation of the dossier. You will receive an email indicating the beginning of the evaluation. When the variation may be implemented, the marketing authorization holder may attach a copy of this automatic mail to the marketing authorization for the introduction of an application to the economic Affairs and INAMI/RIZIV. He must declare on his honour that no comments were received from FAMHP. This mail is only valid for each dossier started since 01.01.2010. If your Dossier concerns an administrative variation or a National Procedure, variation type IA, in process before 01.01.2010, please consider $EntryDatestr + 10 working days as startdate of the implementation period , except when the FAMHP sends you a mail that your dossier has been refused (invalid). If your dossier concerns a national procedure, variation type IB, in process before 01.01.2010, please consider $EntryDatestr + 40 calendar days as startdate of the implementation period, except when the FAMHP sends you comments during the procedure. If you receive comments, you have 30 calendar days to send your answers at the following address  HYPERLINK "mailto:varana@fagg-afmps.be" varana@fagg-afmps.be. If you do not receive a negative advise within 30 calendar days after the date of the introduction of your answers, the variation may be implemented. If your Dossier concerns a Mutual Recognition Procedure, variation type IA, in process before 01.01.2010, for which Belgium acts as CMS, please consider the date of receiving a valid notification of the RMS as startdate of the implementation period. If your Dossier concerns a Mutual Recognition Procedure, variation type IB, in process before 01.01.2010, for which Belgium acts as CMS, please consider the date of approval of the RMS as startdate of the implementation period. For each analytical type II variation, following the MRP procedure for which Belgium acts as CMS, in process before 01.01.2010 the above mentioned implementation rules are valid BUT the date of the approval of the RMS can be considered as start date of the implementation period. For each clinical type II variation, following the MRP procedure for which Belgium acts as CMS, in process before 01.01.2010 the above mentioned implementation rules are not applicable. (*) The response time of the FAMHP will be 30 calendar days in case of annual reportings and/or grouped variations only including variations of type IA. The response time of the FAMHP will be 44 calendar days in case of grouped variations including a type IB variation (30 days timetable) as highest ranking variation. The extra 14 days in the response time cover the validation period. The response time of the FAMHP will be 44, 74 or 104 calendar days in case of grouped variations including a type II variation as highest ranking variation, depending on the timetable (30, 60 or 90 days) of the type II variations within the grouped variations. The extra 14 days in the response time cover the validation period. The response time of the FAMHP will be 104 calendar days in case the highest ranking variation within the grouped variations is an MRP line-extension (90 days timetable) and 224 calendar days in case the highest ranking variation within the grouped variations is an DCP line-extension (210 days timetable). The extra 14 days in the response time cover the validation period. (**) Article 5 of Commission Regulation EC/2008/1234 concerns the request of advice to the coordination group in case of doubt concerning the classification of a variation. Kindest Regards, 2. Dossier receipt confirmation NOK: General information: This mail is sent by the FAMHP once the submitted dossier is uploaded in the system and does not pass the full compliance requirements (foresee link to road map). Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products (FAMHP). This mail is sent in order to notify you that the submission of your dossier $dossierID can not be accepted by the FAMHP since it does not respect the  HYPERLINK "https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/GENEESMIDDELEN1_MENU/HUMAANGEBRUIK1_MENU/REGISTRATIE17_MENU/TOLERANCEZERO9_HIDE/TOLERANCEZERO9_DOCS/ROAD-MAP-2007-08_0.DOC" zero tolerance requirements as detailed on the FAMHP website. All details can be found in the attached Best Verification report. Submission characteristics: - Entry date: $entrydate - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Procedure Type: $ProcedureType - Procedure Role: $ProcedureRole - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. This submission is no longer recognised by the FAMHP. Administrative costs will need to be paid for. Please resubmit this dossier, if you want to continue with this application. All details concerning the zero tolerance requirements can be found on: Click here (English translation of this page available at the bottom of this webpage.) Kindest Regards, 3. Payment tracking OK: General information: this mail is sent by the FAMHP after accounting check, and confirms that the payment of the dossier is realised correctly. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. We confirm the payment for the following Registration Dossier. Dossier characteristics: - Entry date: $entrydate - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Company: $Company - Procedure Type: $ProcedureType - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject - Structured Payment Message: $StructuredPaymentMessage - Amount: $Amount - Comment: $Comments * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. Kindest Regards, 4. Payment tracking not OK: General information: this mail is sent by the FAMHP after accounting check, and informs the applicant on the fact that the payment of the dossier could not be realised due to unsufficient provision. Please note that the accounting service of the FAMHP can always be contacted using the global mailadress as mentioned in the mail, in case more details are needed. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. We have noticed that there is unsufficient provision for the following Registration Dossier. Dossier characteristics: - Entry date: $entrydate - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Company: $Company - Procedure Type: $ProcedureType - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject - Structured Payment Message: $StructuredPaymentMessage - Amount: $Amount - Comment: $Comments * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. Please contact the Accounting Department ( HYPERLINK "mailto:fin@fagg-afmps.be" fin@fagg-afmps.be). Kindest Regards, 5. Payment tracking rejected dossier not ok: General information: this mail is sent by the FAMHP in case of a rejected dossier, after accounting check, and informs the applicant on the fact that the payment of the dossier could not be realised due to unsufficient provision. Please note that the accounting service of the FAMHP can always be contacted using the global mailadress as mentioned in the mail, in case more details are needed. New: from now on the dossier characteristics property comments will mention: Comment 1: the details of the fee requested for the submitted application e.g. 2 MA FORMs -> 2 x 139,73 euro (Basic fee see ID xxxxx) (Identical variation concerning 2 MA FORMs belonging to the same MA of the same MAH) Fee for first MA FORM included in max fee in ID xxxxx (Multiple variations for one specific medicinal product are submitted, and maximum fee for one of the products is applicable) Comment 2: reason for which the payment was not ok: e.g. insufficient provision Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. We have noticed that there is unsufficient provision for the following Registration Dossier. A fee of $Amount needs to be paid for administrative costs since this dossier did not comply to the  HYPERLINK "https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/GENEESMIDDELEN1_MENU/HUMAANGEBRUIK1_MENU/REGISTRATIE17_MENU/TOLERANCEZERO9_HIDE/TOLERANCEZERO9_DOCS/ROAD-MAP-2007-08_0.DOC" zerotolerance requirements. Dossier characteristics: - Entry date: $entrydate - Dossier ID: $dossierID - Medicinal Product Name: $MedicinalProductName - Company: $Company - Procedure Type: $ProcedureType - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject - Structured Payment Message: $StructuredPaymentMessage - Amount: $Amount - Comment: $Comments Please contact the Accounting Department ( HYPERLINK "mailto:fin@fagg-afmps.be" fin@fagg-afmps.be ). Kindest Regards, 6.Start assessment General information: this mail is sent by the FAMHP at start of the assessment phase of the dossier. This mail can be used as proof of implementation for MRP type IA/IB variations for which BE is RMS, following the rules as detailed in the body of this mail. Specific points of attention: 1. All MRP type IA variations for which BE is RMS, received since 01.01.2010 can be implemented before submission. However, their implementation should be stopped immediately after reception of a negative advice of the FAMHP. Immediately will be explained later once experience is gained. 2. All MRP type IB variations (stand alone or part of grouped variation for which the highest ranking variation is a type IB variation) for which BE is RMS, received from 01.01.2010 can be implemented: immediately upon reception of the approval of the competent authority or within 30 days after validation if no comments were received from the competent authority. Within 6 months after the approval of the variation, the MAH ensures that the changes are implemented for the medicinal products that are released for the market. Both type IB variations as listed in the Commission Classification Guideline and the default type IB variations arte concerned here. 3. In case an MRP grouped variation is submitted for which Belgium acts as RMS, containing a type IB variation, a type II variation and a line-extension, the submitted group will follow the timetable of the line-extension, this means that on day 90 (MRP line extension) or day 210 (DCP line-extension) of the timetable the approval of the FAMHP is to be given. The implementation of the type IB variation can be started once the FAMHP sends its approval of the variation group.The implementation of the type II variation can be started 30 calendar days after the approval. The implementation of the line-extension can only be started once the marketing authorisation is received by the applicant. 4. The response times as mentioned in the automatic mail include both validation period and timetable. For type IB variations the validation is 7 days, and may be extended by 7 days in case of unforeseen type IB variations. .For type II variations the validation period is always 14 days. 5. For each dossier submitted as default type IB variation, the FAMHP will ask the advice of the CMDh following art 5 of Commission Regulation EC/2008/1234, except if the applicant has asked the advice of the CMDh before submission and includes a copy of the CMDh advice when submitting the default type IB variation. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. The Registration Dossier with the following characteristics is planned to be assessed: - Entry date: $EntryDatestr - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Procedure Type: $ProcedureType - Procedure Role: $ProcedureRole - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. We will start the evaluation of this Registration Dossier and we will contact you by email, should there be any questions. If your dossier concerns a mutual recognition procedure, variation IA (stand alone or grouped), for which Belgium acts as RMS, please stop the implementation of the variation of type IA immediately if you receive a negative advice from the FAMHP within $EntryDatestr + 30/44/74/104/224 (*) calendar days. If your dossier concerns a mutual recognition procedure, variation IB (stand alone or grouped), for which Belgium acts as RMS, please consider the date $Day0str + 30/60/90/210 (**) calendar days as start date of the implementation period, except if the FAMHP sends you comments during the procedure. If you receive comments, you have 30 calendar days to send your answers to the FAMHP. If you do not receive a negative advise within 30 calendar days after the date of the introduction of your answers, the variation may be implemented if a stand alone MRP RMS type IB variation is concerned, or if the highest ranking variation within the group is a type IB variation. If the highest ranking variation within the Group is a type II variation or a line-extension, the date of the approval of the FAMHP can be considered as start date for the implementation period of the MRP RMS type IB variation. !The above mentioned response times are only valid (1) in case the submitted MRP RMS type IB variation is listed in the Commission Classification Guideline or (2) in case the applicant has called for article 5 of Commission Regulation EC/2008/1234 (***) and the variation has been classified as type IB variation. If this is not the case, and the MRP RMS type IB variation is considered to be an unforeseen type IB variation, the FAMHP reserves the right to ask the advice of the CMDh. ! It is important to note that the implementation of the above mentioned variations based on this mail, is only valid in case the approved variation does not require an additional marketing authorization (MA). If an additional MA is required, you need to wait for the receipt of this MA before implementing the approved variation. When the variation may be implemented, the marketing authorization holder may attach a copy of this automatic mail to the marketing authorization for the introduction of an application to the economic Affairs and INAMI/RIZIV. He must declare on his honour that no comments were received from FAMHP. This mail is valid for each dossier started since 01.01.2010. For each variation of type IA in process before 01.01.2010, following the MRP procedure for which Belgium acts as RMS, please consider $EntryDatestr + 10 open days as start date for the implementation period, except when the FAMHP sends you a mail that your dossier has been refused (invalid). For each variation of type IB in process before 01.01.2010, following the MRP procedure for which Belgium acts as RMS, please consider $Day0str + 30 calendar days as start date of the implementation period, except when the FAMP sends you comments during the procedure. (*) If an MRP RMS type IA variation is concerned: The response time of the FAMHP will be 30 calendar days in case of annual reportings and/or grouped variations only including variations of type IA. The response time of the FAMHP will be 44 calendar days in case of grouped variations including a type IB variation (30 days timetable) as highest ranking variation. The extra 14 days in the response time cover the validation period. The response time of the FAMHP will be 44, 74 or 104 calendar days in case of grouped variations including a type II variation as highest ranking variation, depending on the timetable (30, 60 or 90 days) of the type II variations within the grouped variations. The extra 14 days in the response time cover the validation period. The response time of the FAMHP will be 104 calendar days in case the highest ranking variation within the grouped variations is an MRP line-extension (90 days timetable) and 224 calendar days in case the highest ranking variation within the grouped variations is an DCP line-extension (210 days timetable). The extra 14 days in the response time cover the validation period. (**) If an MRP RMS type IB variation is concerned The response time of the FAMHP will be 30 calendar days in case of grouped variations including a type IB variation (30 days timetable) as highest ranking variation. The response time of the FAMHP will be 30, 60 or 90 calendar days in case of grouped variations including a type II variation as highest ranking variation, depending on the timetable (30, 60 or 90 days) of the type II variations within the grouped variations. The response time of the FAMHP will be 90 calendar days in case the highest ranking variation within the grouped variations is an MRP line-extension (90 days timetable) and 210 calendar days in case the highest ranking variation within the grouped variations is an DCP line-extension (210 days timetable). (***) Article 5 of Commission Regulation EC/2008/1234 concerns the request of advice to the coordination group in case of doubt concerning the classification of a variation. Kindest Regards, 7. Round up mail General information: This mail is sent by the FAMHP at the end of the assessment phase, once the closing phase will start. This is at the end of the European phase for MRP and DCP procedures. This mail can be used as proof of implementation for national type II variations. Specific points of attention: All national type II variations received from 01.01.2010 can be implemented 30 days after reception of this mail, on condition that  HYPERLINK "http://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.doc" all national documents needed to close the dossier have been sent to the FAMHP. Within 6 months after the approval of the variation, the MAH ensures that the changes are implemented for the medicinal product batches that are released for the market. Before 01.01.2010 the implementation of a type II analytical variation following the national procedure, could be done based on this automatic mail. If your dossier concerns a grouped variation for which only part of the variations are approved and some have been withdrawn or refused, this automatic mail will be replaced by a manual mail sent to you detailing only the approved variations within the submitted grouped variation. Please be aware of the fact that in case of a line-extension, the implementation can only be started once the marketing authorisation is received by the applicant. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. This mail informs you of the start of the Round Up phase. The assessment of the dossier with the following submission characteristics, has been finalized : - Entry date: $EntryDatestr - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Procedure Type: $ProcedureType - Procedure Role: $ProcedureRole - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. The national closing of your dossier will start. If your dossier concerns a type II variation (stand alone or grouped), following the national procedure, please consider the date of the 'Round Up' mail + 30 calendar days as start date of implementation for the concerned type II variation(s). The chief executive has the intention to approve the concerned variation, based on the positive scientific advice given. ! It is important to note that the implementation of the above mentioned variations based on this mail, is only valid in case the approved variation does not require an additional marketing authorization (MA). If an additional MA is required, you need to wait for the reception of this MA before implementing the approved variation. On the web site of the FAMHP a checklist is available detailing all necessary documents for the closing of your dossier. Please consult the following checklist and verify if all necessary documents were submitted by you. If not, mail these missing documents to the FAMHP.  HYPERLINK "https://portal.health.fgov.be/portal/page?_pageid=56,512448&_dad=portal&_schema=PORTAL&ITEM_ID=9088418&SITE_ID=56&PAGE_ID=513082&ISPORTLET=true&P_SECURITY=ON" Click here, please When the variation may be implemented, the marketing authorization holder may attach a copy of this automatic mail to the marketing authorization for the introduction of an application to the economic Affairs and INAMI/RIZIV. He must declare on his honour that no comments were received from FAMHP. This mail is only valid for each dossier started since 01.01.2010. For each national analytical variation of type II in process before 01.01.2010 the above mentioned implementation rules are valid BUT the day of receipt of the round up mail can be considered as start date for the implementation. For each national clinical variation of type II in process before 01.01.2010 the above mentioned implementation rules are not applicable. Kindest Regards, 8. Before effect changes mail velocity template: General information:This mail is sent once the datamodel of the FAMHP will be updated conform the final advice of the submitted dossier. Dear applicant, This is an automatic email sent by the information system of the Federal Agency for Medicines and Health Products. We will start the administrative closing of this Registration Dossier with the following characteristics: - Entry date: $EntryDatestr - Dossier ID: $dossierID (parent of $chdossier *) - Medicinal Product Name: $MedicinalProductName - Procedure Type: $ProcedureType - Dossier Type: $DossierType - Variation Number: $Variationnumber - Procedure Number: $ProcedureNumber - Dossier Subject: $DossierSubject * Please be aware that it is possible that the child dossierIDs are created during a later phase of the workflow. Following dossiers will also be closed (if applicable) : $waitdossier. You will receive the marketing authorization(s) or other communication related to missing documents in due time. When the variation may be imple+:;<=@CDFu7 9 : > ? xfWfHfH9Hh)m6OJQJ\^JmH sH ht SOJQJ\^JmH sH h4lOJQJ\^JmH sH #hf$hlOJQJ\^JmH sH #hl5>*OJQJ\^JmH sH #hF5>*OJQJ\^JmH sH #h- 15>*OJQJ\^JmH sH h- 1mH sH h- 1CJmH sH hrCJmH sH heCJmH sH hgVCJmH sH h- 1CJ mH sH hrCJ mH sH heCJ mH sH h- 1     ;DF$a$&$$d%d&d'dNOPQa$F X | 7 *[$\$^gd-t  & F !gd-t  !^gdt S & F$ !^gdt S  & F !gdZu  !gdZugdDG !? { } ! 0 P Q f u X Y Z y z ҾygUC"h3EhH5>*OJQJ^JaJ"h3Eh- 15>*OJQJ^JaJ"h3Ehdh5>*OJQJ^JaJhl5>*OJQJ^JaJ&ht Sht S6OJQJ\^JmH sH  ht S6OJQJ\^JmH sH  h_I6OJQJ\^JmH sH &h4lhl6OJQJ\^JmH sH h4lOJQJ\^JmH sH ht SOJQJ\^JmH sH h)m6OJQJ\^JmH sH z { |  ! " 4 5 6 7 c d ƲyeeyeTye@&hf$hZu56OJQJ^JmH sH !h)m66OJQJ^JaJmH sH 'hf$hoo6OJQJ^JaJmH sH 'hf$h106OJQJ^JaJmH sH 'hf$h7*/6OJQJ^JaJmH sH !ht S6OJQJ^JaJmH sH 'hf$ht 6OJQJ^JaJmH sH *hf$ht 56OJQJ^JaJmH sH "h3Eh- 15>*OJQJ^JaJ"h3Eh3E5>*OJQJ^JaJ  . / 4 G X x ',;G횋yeQ?Q?#h#9hZu6OJQJ^JmH sH &h#9hZu56OJQJ^JmH sH &h#9h56OJQJ^JmH sH #hf$ht S6OJQJ^JmH sH h+6OJQJ^JmH sH h)m66OJQJ^JmH sH ht S6OJQJ^JmH sH #hf$h{6OJQJ^JmH sH &hf$hZu56OJQJ^JmH sH h6OJQJ^JmH sH #hf$hZu6OJQJ^JmH sH G%)*})*+۷qdqRCh 6OJQJ^JmH sH #hf$h3E6OJQJ^JmH sH ht S6OJQJ]^Jhf$h3E6OJQJ]^Jh#9h3E6OJQJ]^J&h#9h3E6OJQJ]^JmH sH #h#9hY6OJQJ^JmH sH #h#9ht S6OJQJ^JmH sH #h#9h{6OJQJ^JmH sH #h#9hZu6OJQJ^JmH sH #h#9h 6OJQJ^JmH sH <OP޸ޔ|hJ|6'hKyhS0J6OJQJ^JmH sH ;jhKyhj6B*OJQJU^JmH phsH &hKy6B*OJQJ^JmH phsH /jhKy6B*OJQJU^JmH phsH #hf$hS6OJQJ^JmH sH #hf$h6OJQJ^JmH sH #hf$h{6OJQJ^JmH sH &hf$h2j56OJQJ^JmH sH #hf$h2j6OJQJ^JmH sH h6OJQJ^JmH sH 18MӿzfUfA1hf$hY6OJQJ]^J'hI|h-t6OJQJ^JaJmH sH !h-t6OJQJ^JaJmH sH 'hf$h-t6OJQJ^JaJmH sH h-t6OJQJ^JmH sH #hf$h[=6OJQJ^JmH sH #hf$h{6OJQJ^JmH sH #hf$hS6OJQJ^JmH sH &hrd6B*OJQJ^JmH phsH /jhKy6B*OJQJU^JmH phsH 'hKyhrd0J6OJQJ^JmH sH  MTvwSTķħlVVB1B!h6OJQJ^JaJmH sH 'hf$hDG6OJQJ^JaJmH sH *hf$ho56OJQJ^JaJmH sH $hi;56OJQJ^JaJmH sH *hf$hDG56OJQJ^JaJmH sH #hf$h6OJQJ^JmH sH hf$h6OJQJ^JaJh<6OJQJ^JaJh6OJQJ^JaJ#hh2j6OJQJ^JmH sH hf$hY6OJQJ]^Jh6OJQJ]^JwTBJp^gdo`gdo[$\$^gdo^gd_~ & Fgdt  & F' [$\$^gd & F[$\$^`gd  !^gd  !^gd-t   rs?@ABײס׍yyeQ@Q!h-t6OJQJ^JaJmH sH 'hI|hV6OJQJ^JaJmH sH 'hf$ht 6OJQJ^JaJmH sH 'hf$h[=6OJQJ^JaJmH sH 'hf$hS6OJQJ^JaJmH sH !hi;6OJQJ^JaJmH sH !h6OJQJ^JaJmH sH 'hf$ho6OJQJ^JaJmH sH 'hf$hDG6OJQJ^JaJmH sH 'hf$h{6OJQJ^JaJmH sH FQt7 묛s_QChf$hS6OJQJ^Jhf$ho6OJQJ^J'hf$hh,6OJQJ^JaJmH sH 'hf$h7*/6OJQJ^JaJmH sH 'hf$hf&6OJQJ^JaJmH sH !h-t6OJQJ^JaJmH sH 'hf$ho6OJQJ^JaJmH sH -hf$ht 56>*OJQJ^JaJmH sH 'hf$hS6OJQJ^JaJmH sH 'hf$ht 6OJQJ^JaJmH sH !:Hop !!z!{!!!"ǧǓnZLHLHLHLheheCJOJQJ^JaJ'h#9h*36OJQJ^JaJmH sH 'h#9h 6OJQJ^JaJmH sH !h_~6OJQJ^JaJmH sH 'hf$h[=6OJQJ^JaJmH sH hf$h{6OJQJ^J#hf$ho6OJQJ^JmH sH hf$h_~6OJQJ^Jhf$ho6OJQJ^Jhf$hS6OJQJ^Jhf$h[=6OJQJ^Jp !{!!"##$(s*+-K.k.;/f001457gde dd[$\$gde [$\$gdegde & Fgd*3^gdS""##########$M&N&w&x&&&))q*u*++>+?+G+K+Y+`+x+{+++ݷݷݷݷȢȢȂq`````` hheCJOJQJ^JaJ hj^heCJOJQJ^JaJheheOJQJ^J$hehe0JCJOJQJ^JaJ)jheheCJOJQJU^JaJ hrheCJOJQJ^JaJ heheCJOJQJ^JaJheheCJOJQJ^JaJ(h 1heCJOJQJ^JaJmH sH "+, ,,,,,,,,,,,J.K.j.k.:/;/f000000073缪iiT(hrheCJOJQJ^JaJmH sH *heCJOJQJ^JaJmH nH sH tH 0hrheCJOJQJ^JaJmH nH sH tH heheCJOJQJ^JaJ"heCJOJQJ^JaJmH sH (hrheCJOJQJ^JaJmH sH *heCJOJQJ^JaJmH nH sH tH 0hrheCJOJQJ^JaJmH nH sH tH 7383a3b3v3w34Z4y444444455@5T5V5t555555555555666P6S6Z6666667)7*7+7g7߾߾߾߾߾߾߾߾߾߾߾߾ߥ~(h heCJOJQJ^JaJmH sH "heCJOJQJ^JaJmH sH (hheCJOJQJ^JaJmH sH he hoOheCJOJQJ^JaJhe0JCJOJQJ^JaJheCJOJQJ^JaJ#jheCJOJQJU^JaJ/777Z8D9:<< <<<<<<<==2>#@Y@AaBBC [$\$gdi;gdi;  !gd !gde & Fgdegdeg77<<<<<<<<<<<=лtbP?+&hf$h7*/56OJQJ^JmH sH  *h8>*OJQJ^JmH sH #hHh5OJQJ^JmH sH #hHhXt%5OJQJ^JmH sH &hHh5>*OJQJ^JmH sH &hHh85>*OJQJ^JmH sH  hHh- 1OJQJ^JmHsHhHOJQJ^JmHsH(heheCJOJQJ^JaJmHsH h 1he hheheheOJQJ^J(heheCJOJQJ^JaJmH sH  ====1>2>>>??????"@#@A@Y@AA2BFBBBBBͿmV,hN)`hi;>*B*CJOJQJ^JaJph,h&hi;>*B*CJOJQJ^JaJph(h/hi;CJOJQJ^JaJmH sH hi;0JCJOJQJ^JaJ#jhi;CJOJQJU^JaJhi;hi;CJOJQJ^JaJhi;hi;mH sH (hi;hi;CJOJQJ^JaJmH sH #hf$h7*/6OJQJ^JmH sH BCNCOC_C`CaCbCcCeCxCzC{C|Cź}iWE7h8OJQJ^JmHsH#hHh- 15OJQJ^JmHsH#hHh%15OJQJ^JmHsH&hHh- 15>*OJQJ^JmHsH&hHh m5>*OJQJ^JmHsH&hHhH5>*OJQJ^JmHsH hi;5>*OJQJ^JmHsHhHhK*%hi;mH sH (hK*%hi;CJOJQJ^JaJmH sH hi;hi;CJOJQJ^JaJ&hi;>*B*CJOJQJ^JaJph COC`CaC{C|C}C DDDDEFG G'G(GGHHHIvI  !gd7*/ dd[$\$gd8gdi; dd[$\$gdi; !gd8gdi; [$\$gdi;|C}CC D DDDDDDDDEEFFFFGG G G G Gƴ||njYE&hHh m5>*OJQJ^JmH sH  hH5>*OJQJ^JmH sH hHhHCJOJQJ^JaJhi;CJOJQJ^JaJ(h/hi;CJOJQJ^JaJmH sH hi; hK*%hi;CJOJQJ^JaJ#h7*/h7*/6OJQJ^JmHsH#hf$h7*/6OJQJ^JmHsH&hf$h7*/56OJQJ^JmHsH& *h7*/h7*/6OJQJ^JmHsH G$G&G'G(G;GHHHHHHIȴm\E2! hK*%hi;CJOJQJ^JaJ$hK*%hi;OJPJQJ^JmH sH ,hK*%hi;CJOJPJQJ^JaJmH sH  h7*/h- 1OJQJ^JmHsH#h7*/h7*/6OJQJ^JmHsHh7*/6OJQJ^JmHsH#hf$h7*/6OJQJ^JmHsH&hf$h7*/56OJQJ^JmHsH& *h7*/h7*/6OJQJ^JmHsH#hHh- 15OJQJ^JmH sH #hHh%15OJQJ^JmH sH &hHh- 15>*OJQJ^JmH sH  IIuIvIIIXK^KKKKKKKKLLLLLLLLLL´әcPB>hHhHCJOJQJ^JaJ$h/hi;0JCJOJQJ^JaJ@j5hvhi;B* CJOJQJU^JaJmHphsH)h/hi;B* CJOJQJ^JaJph4jhi;B* CJOJQJU^JaJmHphsHhi;CJOJQJ^JaJ hK*%hi;CJOJQJ^JaJ h/hi;CJOJQJ^JaJ hhi; hhi;CJOJQJ^JaJhi;vIIKLLLHLIL0MMM#NrNNO;OOPP4PQETgd/^gd+^gd+ & F!gd+  !gdoo ! dd[$\$gd8 dd[$\$gdi;gdi;LLL>LELGLHLIL\LMMMMİ~jXI:,h+h+6OJQJ^Jh+6OJQJ^JmHsHhoo6OJQJ^JmHsH#hf$hoo6OJQJ^JmHsH&hf$hoo56OJQJ^JmHsHhooOJQJ^JmH sH #hHh- 15OJQJ^JmH sH #hHh%15OJQJ^JmH sH &hHh,5>*OJQJ^JmH sH &hHh- 15>*OJQJ^JmH sH &hHh m5>*OJQJ^JmH sH &hHhH5>*OJQJ^JmH sH  MMNNNN#NqNvN}NNNNNNNOO9O:OOOPP2P4PQQRR&T'TATBTCTDTETۺۭyg\h/h/^mH sH "h/^CJOJQJ^JaJmH sH h/^0JCJOJQJ^JaJ#jh/^CJOJQJU^JaJh/^h/^CJOJQJ^JaJh+hooOJQJ^Jh+h+6OJQJ^Jh+h+6h-t6OJQJ^Jh+h+6OJQJ^Jh+6OJQJ^Jh+6OJQJ^J$ET^TUNV_V`VtVuV{W|WWXXYY/ZW[^3_h^hgd  !h^hgd1] & F+ !^gd1]  !h^hgd   !h^hgdH  !gdZu  !gdoogdIcgdgd/^ET^T`TwTUU V VV4V5V6VGVHVJVLVMVNV^V_V`VaVbVˬr[WJ=hf&5>*OJQJ^Jh.5>*OJQJ^JhH,h/h/^0JCJOJQJ^JaJmH sH @jhvh/^B* CJOJQJU^JaJmHphsH1h/h/^B* CJOJQJ^JaJmH phsH 4jh/^B* CJOJQJU^JaJmHphsHh/^(h/h/^CJOJQJ^JaJmH sH "h/^CJOJQJ^JaJmH sH h/^CJOJQJ^JaJbVcVtVuVVVVVVWW*W+W@W{W|WWWW̼vbP>#hf$hH6OJQJ^JmH sH #hf$hZu6OJQJ^JmH sH &hf$hZu56OJQJ^JmH sH hf$hZu6OJQJ^Jhf$hPP6OJQJ^Jhf$ho6OJQJ^Jhf$h_~6OJQJ^Jhf$hoo6OJQJ^Jhf$hoo56OJQJ^J& *h7*/hoo6OJQJ^JmHsHhHh- 15>*OJQJ^JhHh m5>*OJQJ^JWWWWWWWWWWWW X+XvX{X|XXXXXX޸ޗޅީvgUC#h#9hH6OJQJ^JmH sH #hf$h+6OJQJ^JmH sH h6OJQJ^JmH sH h+6OJQJ^JmH sH #hf$h.=6OJQJ^JmH sH #hf$h{6OJQJ^JmH sH h.6OJQJ^JmH sH #hf$hPP6OJQJ^JmH sH &h.hZu56OJQJ^JmH sH #hf$hZu6OJQJ^JmH sH hv}6OJQJ^JmH sH XXXXGY\YjYpYqY}YYYYY,Z-Z.Z/Z0ZZZW[[ɷۥ۷o_K'h#9h6OJQJ^JaJmH sH h#9h.6OJQJ]^Jh#9ho6OJQJ]^J&h#9ho6OJQJ]^JmH sH #h#9ho6OJQJ^JmH sH #h#9h.=6OJQJ^JmH sH #h#9h 6OJQJ^JmH sH #h#9hPP6OJQJ^JmH sH #h#9hZu6OJQJ^JmH sH #h#9h1]6OJQJ^JmH sH []]^^3_q`````JaKaLafagabb c cHcPcccɵxcRDR@RDRDheheCJOJQJ^JaJ hK*%heCJOJQJ^JaJ(h;5heCJOJQJ^JaJnH tH  hooheCJOJQJ^JaJ h#9he h#9heCJOJQJ^JaJ'h#9hi6OJQJ^JaJmH sH 'h#9h 6OJQJ^JaJmH sH !h6OJQJ^JaJmH sH !h*6OJQJ^JaJmH sH 'hU)5h6OJQJ^JaJmH sH 3_q```Kaga ccd:h#jnkllm o=oopr|ssUtZu & Fgdegdegdegde [$\$gde dd[$\$gdeh^hgdiccddd>dddOee1i2i!j"j#jmknkglmlllllllllпzeTTCCC h#EheCJOJQJ^JaJ hK*%heCJOJQJ^JaJ(hrheCJOJQJ^JaJmH sH "heCJOJQJ^JaJmH sH  hj^heCJOJQJ^JaJheheOJQJ^J(heheCJOJQJ^JaJnH tH  heheCJOJQJ^JaJ hs!heCJOJQJ^JaJheCJOJQJ^JaJ hheCJOJQJ^JaJlmmmmmmnnn&ntnnnnnnnnnn o=o|ssYuZuvv;w*OJQJ^JmH sH &hf&h- 15>*OJQJ^JmH sH &hf&h5>*OJQJ^JmH sH &hf&hf&5>*OJQJ^JmH sH * *h*3he6OJQJ^JaJmH sH xyy~yyyyyyyyyyPzWzyzӾӊvdP@3@h*6OJQJ]^Jhf$ho6OJQJ]^J&hf$ho6OJQJ]^JmH sH #hf$hPP6OJQJ^JmH sH 'hKyhKy0J6OJQJ^JmH sH 'hKyhf&0J6OJQJ^JmH sH >jhKyhj6>*B*OJQJU^JmH phsH )hKy6>*B*OJQJ^JmH phsH 2jhKy6>*B*OJQJU^JmH phsH #hf$hf&6OJQJ^JmH sH yzzz{z|zzzzzz{{H{{{{+|||||ôôällXGX2(h.hf$CJOJQJ^JaJmH sH !h*6OJQJ^JaJmH sH 'hI|h6OJQJ^JaJmH sH &hf$h1+56OJQJ^JmH sH #hf$h1+6OJQJ^JmH sH #hf$h*6OJQJ^JmH sH hf$h*6OJQJ^JaJh<6OJQJ^JmH sH h*6OJQJ^JmH sH h1+6OJQJ^JmH sH #hf$ho6OJQJ^JmH sH h.6OJQJ]^J|||} ~ ~}΀πЀрҀӀLMOVWij򳡳{fUMMGM h.0Jjh.U h!h.CJOJQJ^JaJ(hrh.CJOJQJ^JaJmH sH (h.h.CJOJQJ^JaJmH sH  h[h.CJOJQJ^JaJ"h.CJOJQJ^JaJmH sH (h!h.CJOJQJ^JaJmH sH (h;5h.CJOJQJ^JaJnH tH  h1+h.CJOJQJ^JaJh.h.CJOJQJ^JaJ|| ~MlڅKL]^, %a  ! dd[$\$gd.gd. [$\$gd.gd.jklekͅمڅkrsvL\]^_`~~~~~tcO&hf&hf&5>*OJQJ^JmH sH  he5>*OJQJ^JmH sH  *hf$hf&6"h.CJOJQJ^JaJmH sH (h!h.CJOJQJ^JaJmH sH "h.CJOJQJ^JaJnH tH (h!h.CJOJQJ^JaJnH tH h.CJOJQJ^JaJ hK*%h.CJOJQJ^JaJ h!h.CJOJQJ^JaJh.`b+, $ƴqbQMQMQ?. h1+h.CJOJQJ^JaJh.CJOJQJ^JaJh. hK*%h.CJOJQJ^JaJh.6OJQJ^JmH sH hh*m6OJQJ^JmH sH #hf$hh*m6OJQJ^JmH sH &hf$hh*m56OJQJ^JmH sH hh*mOJQJ^JmH sH #hf&h- 15OJQJ^JmH sH #hf&hy;5OJQJ^JmH sH &hf&h- 15>*OJQJ^JmH sH &hf&h5>*OJQJ^JmH sH $%`f`a !"$%'(*+?@ABDEKLMOPVWXYZȴyyynyhKy0JmHnHu h- 10Jjh- 10JUj0h- 1Uj[NNI h- 1UVh- 1jh- 1UhjjhjU#hh*mh.6OJQJ^JmH sH Uh.h.CJOJQJ^JaJ hK*%h.CJOJQJ^JaJ(h;5h.CJOJQJ^JaJnH tH )mented, the marketing authorization holder may attach a copy of this automatic mail to the marketing authorization for the introduction of an application to the economic Affairs and INAMI/RIZIV. He must declare on his honour that no comments were received from FAMHP. Kindest Regards,      EMBED MSPhotoEd.3  PAGE  PAGE 3 Federal Agency for Medicines and Health Products 06/11/09 Ann Verhoye  !#$&')*CDMNOZ$h]ha$$a$h]h&`#$ ! dd[$\$gd.ZƸ#hh*mh.6OJQJ^JmH sH h- 1mHsHhjh- 1hkOJQJ^JmH sH h- 1OJQJ^JmH sH hrOJQJ^JmH sH heOJQJ^JmH sH hgVOJQJ^JmH sH h- 15OJQJ^JmH sH  !,1h/ =!"#$% 5DyK yK http://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.docyX;H,]ą'cDyK fin@fagg-afmps.beyK Jmailto:fin@fagg-afmps.beyX;H,]ą'cDyK fin@fagg-afmps.beyK Jmailto:fin@fagg-afmps.beyX;H,]ą'c5DyK yK http://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.docyX;H,]ą'cDd  0  # Ab5%eX\ 7tx n %eX\ 7PNG  IHDR6nsRGB pHYsjIDATx^gU}>䤓NH!.("RWzW\AP[$N?Oy?yg$/Hov{[ֳ뻾KϲL{<8TKjjQ処&alH^Ӽ4uXf8Zj.6xqްiZk&o( ԶLyi]?D~N7坶.bZuBT?1\.;zY~szɵ:oq}}GIh뜅m_8I$6,0vp=k}EZ'/[akZ6sCK -PZ?`[-'?W'h뜾5uU7m7 duZ7Ǯ[œַC~<[;'m_g|ͭ2LBK$1uM\H\8 &zE~Ѳk*_ߺ][v[.urvꑿrr &qZR?~,[?A6c݅`,RO5ؼC$?j<c8õkc7Llh:KRyW;ϱ&7Z";aŔjo{( < 0'suG NԂȞoE$)۪r=~ ceV*uщyC^k#II,N F/h剖z9&GvNǾv<lgjl~FXoDL?'a CVxdY[xt(beM(?JĿ~"&scI8f, n&fɦ-``X0W؈R1c)cOqZ?rĩsCh]^ͥ->7c#([1Y]< cۓ,m}3m=wأ\!l7M4/K g=byTɯ歒?o1_bm< qgC=I+ X28 w1ycǑx4[W.8 崞Q-\־r~$qέ|;GnC6b*[Oq=֏5[W ~2MS^G # R*yEI&1aYV~ ",M8N#em\vV'/z8N&sb!|'%d%L4Txzd'ÉTkR-sLex[kSΈRG"P,94I0Y>: U=xRz~Uv:zlZX99\`׾֫؏NZ3K؍M,6IGTn~tWsϾ?+o;Y*erT }yh휤lD2r{lUZ<:qs!1KLGnHxv0yG>.%MW9&.ohA5y( .-uNAH=O ñL|-ʸjkI|N:*Гl< @Ee,pL"mkQxz{C0G~<yQfd?5VAvv (onat0к?xF3g禷n6 N=A (Gf}/ Ҏ7nG:TiY@$xFV*|O2[1JY>" #oX^@h)@ D8d`Y,q  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz|}~Root Entry  FPF;Data {WordDocument .ObjectPool ;PF;_1229868635@96>@);pЩ;Ole CompObjuObjInfo  !"#$%&'()*+,-./0123457 @96>@)#Microsoft Photo Editor 3.0 PictureMSPhotoEditor MSPhotoEd.39qOh+'0 , L X d p|CONTENTS CONTENTSV301TableSummaryInformation(       !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~᧔qTPnKISRPOGHEDFHHJJKLMNO|PQwOPyRS|UXyRUnEI\37I!BMSSQOQ\ `_Ӛľxtb?=L Lk fn sY N x:?xDHz~ÆcbLK]Fi X ڝ𲳐%+|oaj։}Q S ȏ߳۹NS zimv>?O qh X ɠKxvuhe M ?jgsuouhM Z;9wvuwws [N 彖Ҷ_peuv{{uq e cߵܬ_tm~}ς|mxyg c{byȄ{q  k_踏ֶxmg qhqcwEN뚿똽꘺Ᵹ㚵Π刬̾~yldntڬ㿿澿컾Ὰđgw>Gޥ蠽옽陿痼敷䖷䔱ۇȁ瑼މȃ|p x zьaGN蛾松ꖶ靿횿뙿晿䘾▼ܑڊԊӈ̅慰Ӂymebt b v(JO✿호뙷뛷雷隶曶嚶喷䕸┷ݒڎԊІ΄~{z~}͂~plon Tbi_!&ץСҤآ㗼둴ꑴ꒳蒲咰䓯ߒޒےڑڅ҅ӄzwxz~z{~yˊvgy o a踴ۤm;>סΘ̔ϔԑيڅ܆݉ᇫ߃܁ڇ݆ق|yzywxwqllryŃЂ̈́ʅČ쇲|sō}zy~u}tynvymrxs{~~rz}wv`rlk겳澿埸ᖮލمywxwqlnmljjklnvyyrlkt|ʀЂІуLjui\ej        '.6΁{x t 嗴܍Ԅπ{sljighimptyˁф|spu}΀ԃՇՅωzqgϹT_e!)$19*0rn h頼㙴ߒۋ؇ց~yvttswш؍ۈzsu{Ί܌ޏݍ֐pokزXgj %+>E$'|{l z r顽䛸ߔݏۋوׇևֈ׊בޔ⍬ہ{͇Ֆ䘷嘸ᘸޥ߿z|vjkĄؤXgj%(?E$'Ȃf|pq 螾囻䚻䛻䛻䙹❽桾ꙸ䑭܊אۓޢ~~~zzshiĀٝXgj%(?E$'ʅj{ oq ꠽碽ݵ}{}{xrmeh~٘Yfl '*>G#)}zp u o |}~ysrkhch{ّ[fl '*>G#)xts}vr yvxz{zwojjecahx؉阿\el '+=G")|xr ttv}yvyyyxupki_]}\~frց䑺]dl %,=E!)pjj oo h夞~}|}}zxyyzywqib[}VxXzbmzߋ_cl%.`w*0<;G>GDLLRM!L'Z*8ꆭص~zyyzywspyyvnb^}]y]{Y|T{T{W~_n|뇳쐹풺푺薻蛾bej       $',̼Կ툰ႧӴ|zyxwwwsqovrhaZYz]z]|ZT|QyRzZiz腭폹댴司撸嘺眽ꟾurqq|vrhz|ss}}䄨؀̮~|zwyvrpqqqsicZUU|X|Z|Z|ZUT|RzU}bt䂪珹鑺蕹陻電꛻으ꋭہ΀Ǫ~||zxttrpookggWSOORVWW~S}UVQ{NxVl}뇮鏻쐼피헽䇤ǁ¨~{yyvtqnmmli`VNKKKMRUTRN|TVQ}MwR|dr뎸菺폽ꏮڀ}~{|xvvsqnhfc_ZPGAHHKLOOOOQTSST~Xbi|爮퓸씺둹ꏽ딻斷〈~{zy}zrllf_UNHC@ADNQPJEGWVPQYbhl~ԑݠ襲礰䥲ߨݩߦ䣻鞿y6=l+j뙼✼㕳ـu|}޵ݩ֗ߓ~惸{〉فke^_^WMC:47O^[J5;[`K^TiyѝᘊŠ»ɴ}ͬɼ˱ӫߕՊӝ뚿i lv9Kߡ࠺݋u|ϿŞȝԲծͮ͢αҺʵ~~{}slf_~:;DX󉃏͡ӞΥȮӥϳ♞ֺn~ȉʣݬ٬Йu}vkxZgg_ZVRk<_F`EQNGq^Pkcnra{R>AHS`I0GJYePy݈٣ڎub:l[0]G"N9@7?B9O+V(X6Yu֑֟֬hh_%12F@#%IFVtoe k T^XUC : H?N!L&G-E/L4X3W P e t z&` ,K:6N'c7c3f3_%\_ tg "dAHd} vx"XX=.'SPO(W-AyBNOBVPvޓՊ|Q+^OJf(WÔʳϴ␲}ϋʣs|=lY@@W1Q%>ȯZ sxq [$޽Ȝ^ms vs U }պu709ATr~iMDu y [)F?~&*~9zE|G{D}6}YzlS/k | U%~rV)W _,1ɹƹ­/ìbOUmt֑bhs}6D׽p}i綐tFtŧҾݿhGrrΜgaPv | f Ɨߝ2,:0/r  f g6IvaWOKB2*)3;OwzqHFp!~q W-E>-.|7|EHHB\wf?ZhavY逶= y)2k3>©aQTӳB#)δk!aҶlo |Ź鯞ʼZElƴ=r} eVtrhSEfҮʍ;Rp fk2]~h_XUM@4"'/Dzkx78^ n cO5>= 1+(7=HRau؀sf d c:XΆ܂ݦeUpa%cb 󨡨euc>Fs#ܣF%.ʳSs_c F8ss=USZnnz>F_/;it u}1Xutlmp{y{{Zg듲uoye@Hƍሰb!~m`[_?!9j&rwg\uva Ǭܲ˗ޭQx`+ܱF򺒚Q v qr حH-2¡S^z {w h+2X)9_s u,Jqmmoxlaw>My ~`m׍判ďjk ~ XXwfrUiWqrqaP_`y{e àٟʻȨBu-ԶMc!/r ^g忧K14R`{zt g*1\-=cylv,E~vwvv蔥vr_֑ԴX ~mr2Lusybe {Uk3ʇ븺}{}~|O#:東mvt _'mrΛ❣i.Bq~*uÚ˟ۨO\kc xf|Y]_gSa{wpe(/a/;g||3Hpnひ편삷qdۃ靾ݜGTpha3v֌fx{b]l| sq~ pq6Mʝdl_   !)W(8z wubǢtys5BqTj`Fc^EblSicKa[Gc[Ah{Oc9iS>_)-B#5S $4}'uսꨲRૻj! u[L#)ذUb|vne*0c-:h|~*=~}ᆩ߈yɁځrŋ«S`lx~b mEhquɢפj$,o\nz lv kv2avRfd#8|@:EFB>G8;)3" ZlrCMڠKPyv蕄i>GVc{wp f+1h/8k|}z0΋ڊΗѤ؇Ų˕c26^x x\v8amlיcqc'_}s^>LMaj.B`Q2:::9BJ]EX '`-H"mTPiVPs_^eGQgHZU;TgUmSL^`T`nNSe#%j} dģqvǏ´ĸпܠCo-cuΐTܟYq w`J/6Sb{xr g,2n5>o !1}gxZckmxTxe5OO'\ok bk*Luxxv٪>HRl|}h ZʤTXq'K\>!3.63->W;^/ΏB hHIcVP|jfyx{}h^_|TTr~ l~g k۲ˮRqa4vMq-:f xjDM򾦳R,9P_x ws f*2r:Eq 2ǁfrDHn*$H4 5l Cu7g.WZK L`pV{8jP֟|53b ppzd^ğU[q"CL/ 3#*3J5V!7J_i&7ۦ^iy ><`y{d ۸9 vyIfu`p~ ^ cs`qM[v wr d+2pNr zle,5wJ^by}f #{qgg|p}y|q{dZWUUY`fknipj|*jt}WYjr5aC8.4/5;EX CY$,[>PU*Elp m k#.g j ױej[#&] rz htI"7?Or zo g.7yL`bx}e #ysfelvnaZ\`dhjkljdidĸ})nto{Vbr=_ID6)24;IZ4T (D3|Zsϯ]w| _󽧳m o ׻ahe-0w.5Yp{o&1縈C*˸>Nt|m d,5wJ^dxe!ytgejrnfdinuvvrmhdfjȱwp ~ Xi:l_;15/4G[k8Y-g-CU7{sk l$C򽥲ln {>F_&,g$e dl 7:κ? ߇:Lr{j ^&1KWq f xuiggosvzׂ刚쇥ᄪـ|ҁ܃ڗ쑋q]uv'#Tin#:umXZTL\gfp;R+0۰V)Ng߽n so'Қ򶩰f ~h t8Bb)/@V\ iee 䣩wEPg9D@Ru| o f.9QZx f xsjhfltvy焩ꇷ߇׊يۖ앴lL[cH[r.#z-QF=Zhh2# '3"#, *#+xT*m+ y qpc |}e 8Iv/=לPn ykNU@ px?Tu up.:Y^u|d ~rqiepvwyހ脱숵싺挿ގّܔߢp;MZ-B\RR U^V򴸹}pyxtptunvt}sx|c:N/ڗdQhxf.5꺤w wxm!@a` u|sMA[ ~ v,ފ^_ju r[{xnqiwz|ㅲ鋶둹앻p+GI*KLaQ ܏U &jIPնXz vhﲗd{ hޠ9z,Rfr ~fNT6Mux*cldlmUsmswބ僲茷쒼_/[2]ry28Tj$.Yi|y s&\z}щՋֆ݌喼嬞P(h!pt!,̉H Z$}FKɭٮViy1l$)ZsɊ˥dz𻢸yc|EX#(m m YLg)6^x~e6&] se#u:Lfurѿ˱am;Eux~ W UTˢ՟o/?d,7ɚAFr`dt:9pyۨ۾fyl!yxu';w:YcsՍ晾p^jDX*zgemm侀Q\=^#)ko{y`HXtK]wDWG^8Z/V/\7b-QO2B5$ 8+&6(7a{|};9F% D'C e!,6A1D1AI R#)3U0B9"K7Q1I_q|VcI4U "<$4R%Xm oj d aG KP-F*; (^J,HXKiԎ㘽ܦYnj!hkTS> LxAFRZ}:C_#P QDL巺yxwzİɫʫ̟ͫuzmt~}ȼðиļ걡ƸнԹ׹܌}łnjĒff}iulii^`^[X_ًܫ̻ĒYS{ULZ5-IT$$f24vDCfc﫴䆾߆ފ܋։΂~ȃ͇Ͻߕwvuwxzڄۉߋ䎶皿ޅߐ퍹芳߆܂ywz΀΀~ƹ~zxl``aekrۀ߉勲鏹ӰΒd~DmR}x3`o+T^BM1F+H/J!1C#2:#5fLetđ߭xrtv|쏮牬|nghnqrq퀿{uvufQ_\^adirz߇苶阾ΕSaX+AJ &a&Ds<[u|vlkU08Jd +";^g̺֟yx郥vg_]`ckovw||{weP__cjopx~肫釵閾ӵ}b aQW!]lԸw>e}z Pc>E}|{z逛ynd][\^hmzlkpuy{vqjZNWY_gkmqvꀮ숷׵-@_]XLSѨ{UJu&)F~ꁽwsx댰ꎬꍦ舟⁙~ohcdcaab{|rnqrl`XW_`dgjgio뀴ggZ g &e+uľhc,M J"p߀zrq艬⊧ሢ߃{sopk}f}jkg`Z}}~zxuibfi`ROVXXZ^_`do~⿾ťf,^ oko=ťz긭ؠhM$V4Y偬|yzx솰섦ャq^~[ydggfea_~`~^~~|zyvqligd\UOMOVTX^abhp٭o5!b n q i1kҩz{揄vAkA 6pP튷vnyzpmg]]}cddddcb`}`}~xurppmkhje]UOMMNSQUY^aks©d/7Uk c] vթupqwߕ- LJN~yhast|l][~_^`dcceeca_~^}Ӟ~}vqmjiffdd[PIHJKMQPQW]bkwĮ߆Ikl$mcl{ERxlii|蚭L_Bbkmhgtem_SvUx\_bdddeeca^}[|sǠyrrnjfd`][YPFADGHHOMPU\do{Žwd&}{}N П~qjfo労]pjijxez^}W{VyZ~_``addcdb`]~Z~jzphmifb_YRMJD??CEEBHGJRYco~ﯼǮ؅7a'p $].8Ҥtighszꅼir]WVj|erVsUz\`baaaddccdddbj|~}yutnkfc_[WMD@?=<=BC@>BBGQZcpޱ~p 0 _ ݇n`\[aj`U]BFHu]ncrYvW~\^`ababbbcfjmprɇܛ|{|~xrnljg_ZTMG?7179;<>>@@@BIU`iv򾳻~lyqpt{|rryp}svͨܲшNgp w=L|퍷zvqqv}jVQQWaCAG1xGP{\sgx^~YW~W~\`bb``adjpvz|҅כ}xttutrnie]VYSKC<5.)48:;;=@CDGP[gr}ccm2 %%   # %3$튱|~\'{ Z arќzwrjflqnaSGA@B|G@y;zAIN|Zxb|][\]^^]^bdimrzلኪ㓵喸国~{xrqkgd`\VRL@3*')+./49;97;@GL[mw}^ov0'd^~hhydpbnhyi[{$a~!7,3؊tUy } T rޗ~yvokhbYTXTPG=:9>~AzH}FDGJMU\ZZZZ\^^_eiqxـያ蕵}xwvwsgb_]YRIB6.(#$'+..36768AFJTWWWZ^adlr|އ撲휻~|wrj^WUPI>4,!~~$(,/145459BJScwꃰ鉱◼Akj3 .D+*L]vyte8slkYR|XGA=95.(")%%()'')%$#&,5?D@FGB@CBALRTW\bhnx⁤䋮蕵~~zywvsoj`UJC;2*~~#(,.115457=KVepါIpm!60E-*t9Kwt uJ*v]OSD<82-("|yy"|*|.z3{3$"&+06:=ABA?AC>-" |{z|{ wx{}|||} $(~+}/|5>FNcty}ߓUaw"6% ,,@#9[ zyk UXzvrigd`^ZY\coy֊y;yw+|}'횶|kfgfgilqqoqlhgeb]WG<5/*#~y zzyyz|} }~~~ %&}(}.|5@KT\wty史:gj'+"7;(+ۺcv or!'}wvvuuuwqdgyt^1a m jn!'ʭxic\VUWVTIEC@?<85.'} wvwwt r tv w y { } }}~~ ~ ~!|"~'*.4=HU`ho}莱Dmilo&'$*sv+*/+LVa h Ƒqhv웑J+Sgjk)-ߨwh]VOKD?<7~51~.{*y){%x vuwxxvy{|}}}}{{!|$|$|&}*17AKW`iqz뙺gbf   '++'*.)-ȖV y o&1L(Xhj j)/ui`YOJD=:60,|+z*y(y%z$z zyw{}}~~}|{(+/38?GNYdnu{䈰z~z~vyvz{wx}w5Af {wmU&` l lj$,vm^WOHA<741}2}0~/~*}&{#z"y&|&|'})+,/16=AHNV^gs{ꅰ犲嗹򽓟b s tv"dڴ[ lv} {+6|vld^XSOECB?;888:;<@CGKMMR[ahpx델떼Q[^u il x-*Yq~v|&3~upjfb^[XSOORTTTVV[_egfmt|݆]aW nnx IN] w |}v/~tqplkjjjfkosy{|~ʿÀQWdp ^PZաfmju`5Wp%CY3S"7_;IeKVhJT~P]dt٩Ȳpvb8BG D])z,DZsfsčuVgl9L_&9I%@W1Fdߴʀt$z $dY GPƟӔi|J$U c "ed $Xjڡ{)?^$d }/֌ʙUdm"e"_đҠp|T p &n 'Z(k~̊CIe tc ȇj?FY#\[b(˘IOka qv~|wxn{ql~pv}w|ipquq~tyzzxq5=Wc Ub#bys4?O^hbga #"#   ).(=Je pX b!dqŔT5|RfX]p&P*t% $++&p&[)-ܱgxq}u a PWǽJsyMqW\|K.3#,5 +: ( "3O6hy|yw!,̛𧋳\\Q. 1316360 20VC3Ap sqKW\\~T0353868242 W>륭}x rpXarJ 3453758255 M!2\dn  i~/;Udk B 455263726 6G$+v )s { un cmRei ? 554030516 7D%)⸹\| o|eܑRel A 542-0.2/5 7F%,a nx k Uaw F3 21+ - + 0. 35K!7^_uus f X_|B220*-+/ -34 G~88n{q _b]t#/7<<<<<B70"-(?r1/{}gh ׵㶳v|prpzyk~ww}u98ns ýፁ9++# = Ja%] e x lx rS VAGJ hwc^k  {~ qҎly0>E^ o}l U bekkd|gW]Љn`uhQr87嵱߰`Q{rw ޚZ]] b X ZVyFCҫǗ@ R^Ju&)|}ԮMV!d j a Km*1qvꪺ͈ĀKS`$&> Eb70aZӢzEMb!M LRI FL S \'o$89JDMW[֫Mdiq;wdUTTܯCEV|/4{;ɢռD댵>] VN?)9 &dO0HJ2qV\.7<1f,>;3cegK{YmAu2hq덖n7RjXX-WOz-៙zk[&OV]8(eFk?ݢKc⨸{0}{6N V'}!/E_oHL=׼Vk}w~,Ҍ!^w e*67ig1{HL]'t`!NbNą#m=nwF`! A0lA8c%Ta%f )ǔ|$',SG;iGaHnV^1c6_ #70k,C>|ƞح.w0RوC{>O:x{-J# M&~RRc걾[$9-w+"~P̙JUb! J$Wk3/ ?OzB: *Surwy<> gJW[ 8'hi7-'ܵ~÷~W}oĵVn\s %LT{AGTN)gE9V$vmSSR*ͿT"x|8n}qnq1U_G+TnšxuZIg7Ԉ“?H4N8Nvc\yP ekL/+ d+uI=}Mj:'(1'f2S73?a͕e_ W^ [?I q4 F%VH1w$j_=9xCv&;m`Hƒ,ql+JIܺ[!\ H/v3A0fIE|,!L=c(φ:Mhv[ TFv?.SY:NRN-juIu(ʂ3We||pJEZI`$ߘId`x X_FXUꇆ?.mm϶fvl5?]#(=YiL=M6bn> Wda7Y C0&YQg_Vh0^+l(Ιl^nYSQ&\2DR!?Sg`$xE'Ʒ?}{jN=J)Y1!IR) r쓂 %l1t*/opEII@ 1^߸qCO;pp}#כfZAF!+V~źOV_e}Dyex%[ &l9:8y?^R E?MAb"$u*ſmQ.s`ʏgh9>{Oz%a%1Qt[ug : Uo\<@8Zk"(_dS[p.֤|3z>r5*ROy8Pmgp* oO_[aԃ=ųΞrJ%/ȱ^2hb*ԕ˚S_vCw=Jw PIxJQ -4`Qѥ%R(Ml>'΁)ax gRo ǰq-^-5XD'l$fڡv-ww{}JrX+*i$%xc⟴WwMjON7}@rVsIb>A0 pK|3^XnG sa[knhRɫW`pqХL?&pTq =s0Giԣǘ,(e-&I6 3TW@6_WLHf'"jkحjZɸa$&,!D7"Qdx9eHi8@."-ˡc$_A@zCD]o{pph7ɬiUlFд81=/<DaT-[ ,AV궋w_~K?ΥL/A*Jrcc2fwjP%a( J&&Jԃ%^YJeH".W&ywCX7HRzr%Ce9lC/ #fMQ] [r.l/_~_-?.ӎ?8Z}T=PAB1O9˟tTO+oB4 S-Zo:MT[bx©vpE@|GV= @^3 qMe3I D' N?"4qʳ_6 yen2 AWdcP[s!5筭cc3۷O5kP7,v#U1 FX ?H"NF#Q+<*lXIj2Fd@.;*<'<☿NLۻ;szTtr= U<,2G{/׏{,]2Y؂XVi ^YTV-w߹C}?ul:U Q87ľ1HAIG~kfaVr`صLYH4[>nBI0x(F7 pi쪾L,y,(ϝ[fU9{N='(\3qc 2d`yeEH T,_ʌBfYwtGZx޹GΗ<ϵ{<'5bhX GA)<\7@!ɀl{ZԨVVK۠Zl#O3s 7|z'C}nCoC0I*HZbđ'̽ȃrxnԋO;rR2ض V RV'~Ѕ'MRaUy2?-s+!;!JAX/8!I8NUA1*'3=UL5WAtyg\0τ*a> r'&B)dyoD8?,^zAiq^R.r)u._08<;;~ჾkN<܉.dlܗ:z'[Y[ j*ڎ%9Vf f0r?R4]x3ӕz-Ĥ†5t%ILWAH\vkd9ee&,Hds=?(0j3FyUSA٘7[ q"HXuhrDu׹sB`D]IL%=庺Tl= KY/uu)D*@>;V'ITƵ BAAyNrE$}Ƚ=I=?8[yvKZr*~Pq|߽osW隣Uʤ>(BY 3 Jb[F;n>Ǜ|+('Ji獟O{#+]ղhilknF;,tm~UX?]fu/8pɱc"&;EUB Cz\uagv(Ħ|hǰX RV28!$~\y8z~aE9Mʠ1Ya8NGQ{<PZ_{jJi~Eh Ge5y բ-DA#*C $$FWKE*6P=J,J}v6!J#* g$'%}rA>!<0껲cURrPߨTƲM`8 >@cY'4~:mΜ(Q:MUc1x1Rͧ>uh%s0UC&OI%0(c%>z-wxwwpe}X9,daC*"OA Rx7v:_xD\*z*M$5B$dБu}n([8{xt-8;w-[UY;yq.0QGu(mrցb 2/s ϾW,D,ق VZ=)`ƛdң? j:3mq=Lʁ^Z!NWTq0ZYl޴QP[ Ԫ^&ˢ B7 PWm/[ۃؚ9k t'PЛēPqR"LwʃVڝ78N{|tce/q6hķnin/,*8O6gPCh"[,TQ`dR›,qs+g] CpSvwAXI,msQ}ꢜmwPĞ7!Yc[V?{r3*f/qwbO / K&kɂTI6KmO7[33TszqaN[+Sg>[nEB_ )C37u_]FKX<2imHygPWb3@t?Ht"lʋ&El cy. `s%d)rMs'itn[I0\[kLlSZ;`GIHMv̲g 0*e1Wm#z.Wշ&V8>g+~5_櫿Ze;ţK+\mJ4Qݍz_Bu/&^Lz07~o>isjI)C\TaIgҧdk&D*^i$#b#-|EbfVRvUk$G1Ĝ |nT$D&9 Ӎ:o/٧ڋC ~Jt(ضF0U6] e~}S! ozGҚ:*YPGёIi(&~R"V`/tRqQ#fOn7JD-P[E7Ɲq4#U4f`q{9wSÔKvR ͺlrQnTZ&_ifMQTrcC֔J.P:+/S ,?om%9"IJkm[O~ş!y^÷TVqJ0Y) *ǫpP eu% 6|,,NmۦuiKX,a*I Qf%c]cY鱌xHyx)V![ONQI]/Βc)ÞH ﹣ҷ&P1W- qmنJM^8!-M>A:B^,X.Z)5jfCtխJZQ+7FҬUyBJQ+ffYΕW6Xz A;Qxr^?tɱ]P>*9?Q-sR #Be>p ƞoz o&OUϮxuL@冦 ӉεT XNbN$¼# "_n՛V!!;& $XDPbKU6dJ.zy#lx*z2 l^[zq}o~1X1I,$w _"5EpȆGEB5!*r\ `HY\eb &݃-wih?yPѴ $ VhAΟJ*f$(tbVPv A^Tk]VvuwQkVNutRYi[VҨ7,EEHT9d}Ȟ*#M=ŃbhJe 1W: |#4W[58"F _^ֹֽX[!*!pډF 'A$4Ua(LykY&4`xi.A}`K۸32Y$)UQ[`F7rrQ?ЏY<+--g#(8 vUVbQd-J]<TWY*(ZBjGgtaAF⭊Ҟ#+͆\NAc4̗ZľUץ%.WOփ]zdS %6*&EU \9KJVoݾΠ<SOT0!Zɢ͛EJG0CpУ9*#fEs*A9X[i+=m-x&` )uJP?0`yVysn7܈ (/oDԒsymvB=˵ȟb?^MV0$z.y{B8OY>RJ 36`億xfy?f _p.`OY&rl(6u@ů}Y<հ&o~}'c>a˱ưh3Ӻrؓ0c3pQ yüĒf/>ha!BS4R[j9q!<6HRUidf_يmR"oQRFJf[)&K3 nc EOEy-mbdQ=TȲK- PE6[.5);l6K *^("!"CâElN-wG+Qwwar𷛗-zINZGGصjI0DR %v;>F H4WuV7Q %eC1YblԦA.!<'ߨ- ՗-IIpc46!Di+k\v!KA! |ʢ ^8!L0>WGJ3wQx0"n<+ bGYfbrl"h++qqe+en=AYo U! }WY'KWmE\y@nSwE0P-!/w7F~;0>%\Ql 9 #bmJ9L9ztcT^ dO 07hX`TD5\f\Iyse>N-_~3_ֱnDwnvF]7ۙuKnG~d~/< XƾQoO~gSA#%QO}V|v魧]&pZ V8Zd!37<=PQȓQS RrEo%)`q &6o^;](ĜP3QC1PP+!@J pD`=tVgภQ6ykɞFʭщ; q-Ki..9jo4녂/" kw~ '~C?;U=Q:o՜jPұt3=zy.{ዴjY`TӁ['ւ{T+vx'`>m;/EaKwDy wng뛕c"A`Hk;Ք;c( ͶlDwb .  #Qx1̻1U,J{ TI"JI[@)/D" HPm|NƔ(F@YDCư׉Z62E*.$ @ Qi"E툢sd.܇2d𔓦؏'֣8{f3W[.F|0\7>ᄓn:@[;ǿ{ac$` CpA!ˊvsyyI\bH9&!E/.4 3r9 2З[4C.u|[Qx!dplܔr؁ Az(z'sW)&>P0G)c.>f(N; @:c.צH/sx]v/nf9x-S8P56$Ţ3+Jz T# %4bGLb*NS PM<8.ًsF6W м#ʝ 563ȷdd'J'W2&`ӈQfXGN$ T}Ժ0B(*9%V H8 GAZ][3F! p`n@QFQOb\JRPJRN7}ea¯RZ* X,RTZ؂ذr^ږN~)k6ӒD($T|xfDOXF2i` h5_Ѳ|JR^KOX^RQ};*M)X!hj4$ebYy1wi XZ{稉NJrY\LQb IQ"Wq"~Ҥ IBYsH,w&.AexU޲|A:GNY<$ͥW5`6jȧX 7Eǝ;h=ryhr[RPᗢ]zFyI`xʭojآbeJ^QQ/㷹ޢ8xV .=L5eO DçA]z>đ,jAV%DfNdC, "v%EA\%搟ik KCf4ZHP j ~;&p lf(2@o^=1BͨH Fzxe6Fe{U,F@G(YE::YR &LŤ)=oS3=AoUS:kepޞ& c"Su }\XywQ"7P 1mS/'-769sV|27]8pGNzT`ٍB8WgVϾ(;:RlG}41v!FquWkvnƶK2u~PT)OvK񃤏]yjWeJZ0ajYR%`-; `dF8!ڪ;R{A=zCa6|bQ3hs8ݤ5k!`d&Ϊmj#-x]UNșP 25{Z@@"WkXCP^K}S*dkae?kڒ.@XN&Wސ&AK-+K-M6xm73rw2X`d,yܮ/][np;W*z H?_/,4܀ y|'#u|TM09(T2B!6֐0~9 J<;҆_)FWCC &_6j@D&M+3]T.GcPfɡqU^9 g(X]-&=_+8?g^Z_O\츌{ I膣C/Q49ڶJ6m<̹h3rMW`GD3&oQHWȉo=ۚj=UOgN@[< DotA;d_kIԔKKoN_CZU쭻۪NfOzL;*ll5Z߱DKY47W1zR\uzSYۿvU0e+Z}q`fK.+=:uŹƝ, DӾn԰!٫K('T[켉#qH_wYkTsnzGɷ"7 jl0 2yjR-zZv\h^s7JHӴ$%du<ĆrG h^Ǯ7L\7JWmucW&Mu {Ii}.}mvwW1.v7ڄPƄƣʑG/ -RZ|`<}I!_W]n`M 4nQv'Ы21xL E jjI&(bN\,uon<>`bN޳rtž:I{) yGl6bo `gzpɋ7SЍL`X]YK_gv[\uťsXyntsQzo-/z;(~?to®me_ Κr7=pK͇NpXZ:Ve}t%۸u4Q, '?R&j#U^R^asG;n(~w' P*ӫ_}:)ĨBTߔ5)d zҨUr\h\7i١}tG?lI<?˿s%Ϯ. KnNg46gM,A[#ғAZ-B__Z>w\bhkDS8G wz>s~xp (3r_\ab4ɦtn9|,( `1j[?oNLnѷ)C9E)lxLd$5Zz<;>{͚aC {3/}~w$~qk[S\ZFV踧$zIW)USkzSf6}/ߙg^_Ű-W <újoNW?2Ͻ]Y2w̧r~͖ojgX*K x'e6zuZƀ߬U|v42-ELܱ @SXF Ų.jS ?FrTUT̻(Wg9s/RI&?4g/O9gU+ZV`Ԍo_vSM㞮w]+v#>3Du\FaEzz>s[:3};vlN9>&>n9GЛtʠ;)Ҫ ؠ/ 0J0D΍j7Tk]7LysG‘BYK,sC~7>Sh:NᦔWcS=sb6Qؘ߽FyM]RXת5]uzS l7_s?+xJu>( U\et^/kPClVjg_rف80Go7P s%;^?I=ys,fz{Q )?4FݎJ`|_ њכ~Cθ'6n 9S+Գc˴Ǖ\HV`mc\֖nzӦ,&2-k` u FITݻӎ%XU9Rs.ʶ)cbZ--q8XNt;#U@.Qgm_d PrFА!.Aȁ䫔7k{nkvWwn,mPmP!gwX!M1[2]^سϭ/4fZn¹ӀԎ&ѬI% 䢚PrCv-s[WYJ.%iuϛ>ɹ/g?Zޓ$H/|tݣ3bA &:'uu((xdʱi aTV/}`ƅ'zN9 s 6ͮ2xE# >.ǟfըt`vm\h~Dsz/tfw=G^/YLSiW>oVg QqB}>B*x9g^pg< ?ԽǝE#X+zBp "Ы!8wKr{lQqc`tS۞E5ܢL+ALZ`Pw3g2\A OiP"p2d#m0C6'S8mF?r+ )k1&~r6s]3fسmsOk.f !'+dYiA\ڲ]jZ4x1[;~%W^ӟqU_/}yB%&+&|Q埘 Ht80R'˥ Q.[qNktԚ*z[VZNǙ13p.٥GC.rB%5˝f,,^W޶2B fumwn4.!07}IsO;w嗝tN:]PV`"[6dDlӷ0ݴT[yV:H)T2kSiQh+/DAc#~= tͲjU$] ]Oj1h#$,e/+SwWfaB|Unn2t=;;Oz &U?'+XKDsƛ~~7 ֪\Nw%L:75B ybtȂ^ @TH@.B!ЮDZ=4r왖Tb? j-W)'^ҟ~iPmi]1^3EIJzFu){\}vG;}'15'TM;_WUkִrq\8i_musSiZ$Mg t1kiU~Ka"0 )^aqxxI۸[zb{5?]-n6Ess =-M`(oqZ*m =xrjuGkk>W{&eip}vҶ]'>G~5?O/ROeK)dq]$ɜ'(EBUNB  NPSkj_'[ܱS;O9}@ 7_uzHG\XbrMތI, { gTARQbViJcVcƯTiW3'°+x EGȥF Z Ŕ$}3;/~ !hp'"Mv:VI48%nF_#G(^5 qUwrmz h8;]iU ZTs 3U+L 3ug(}sCJ;YFҪFR6RZ1C*VKNLп"Y>&~m9!hǎYga >δ)W[ZM֘vyxezQt 11zbvrS/v5h8"Khe!p uYȦƂby"})=]$o\b_/E?7f0y6d~_ƒ^k:]գ9y!Г.z){7Fs.z\ K-kz>,) :ϫ<*^RmAv늃iTkHWM'l=UeQ⥯oܳ63}ԯ!u*PC邗p4rj<>6m(hSJ6UZ jZu>mӚڎfyT͖kwoPN3;gsٲ0pR;Ml'@l̎F5Bk9|QPu3wVZpVH{äќ$,Mq\5 D ak!\)8bO2.ʩpRE?@8lRX([n/+C'lc^hTīŇ ʉ <5A/OŔV8 @,u ?eeQ*V ˕&zj AO `X)>̂(w?w~XeNٱ[5QQxpv"GZ}Ҝ~Yw]hiV)Z6V":ۛKc(՚ف^%3j:c } C8buQi7f7iA6~)h&̽L#r+zie9ڌ[QAPn$MsFZj$l<f"P3dXj\Vn,l>?؟N[)f=@Cɞ2DF&gQ`@j]k`y$BGg/~Z6r9œ.:Wp6AO}&ϟ*U^酤D8#$h:7Rw[fi.ΧtF,Vm m{K*n1N;cHUM)0ciSڵz4U՛ez֨EaImceTt2(R\OE])' o?7?׿0U =G-p4s N>o b#cEt cia{TqR3>'n## FP55\Ȉ1^k(c")~e":Dp |%E2i_1&f}ϖb؄B+2EMZTP$ &4eqՔd("]BTJ^Y ӑˠX#Aţ%^‡A/6jKVaXW03BZsRZXFrދ_eq=&SC!?cJVKyBeh|_s={x 6-%SdxsjUŪXlmkS4 2q ('1i!+h#4<0 !s T;GdWʾ>!. dq޽{JQco$w{͟k;kM[Z2)dU4i}_f+Aw'%W1$gN +OK~Z9\8 dޏ[TT7:"vHe4|;a&Ij傪5_ZwP{~P ~u%/Hǯ-T~01@e&cV<; Gf[z7cecu1,135Hv`E.H]Ϟ<5k7~ٰ(Z- {<@T\mqfU@kKͺj݌,Zk\j|7U2J"SRz)B|}cп}}ϽCu^rSd캅:Җ$I4EٔMƢk,'dJ:5?ZBR>8;^ EwB#cդzZq{nJccXJg=9ŨQ5Bpoz|"L|zo>O];{iꤽnyʰJѕ1# H1GP~C:Dyq̝_BA6ن,!cƕgV=41w0<̿Gz8(9^ $nhZLCD<@]fklr wIzԤk iPJ.]kdH0ݛb-@ "UR[:Ž .>TF^ɰij{F<:iͥ/#Fkՠ}Ohn9 b;~6"dC3o^^h`O{X :ُ]ݩzizyĉ5 %_g>Skdz@LD<sQ#vadSLEeSgQO+D"ְZAC87F\kn)-F]-xZjw@}q7"L'[g]Ts(W_@Z9}?JY1K {^yZoz7)6Jވ۰m{m2kҁ(U>6&o9<Ԭ˻VLW^~M_y7Bmt @a"KoTTZh]Ѯ!Oձo/pepH;~؜Xmλ{>[K#ѡ ӮccФ#^m5JAv/wӯfRBTk'`XUԅg;3so!PQm+ &tIQ\LZ5˥H7]`4lvv%}j[~YeNVnƾ~t^ S;zw,6i3F?H^|6euڝTR/~Ϲ2As796|cԜF/@orvRa1w 'ȷ=oud(mOvJ{!rJKq;Q6qWdTGIu3G֭E;}sN)F}`N>:JQ|]/4>"9 9(#dD; i#S>vwka5k5F>Ah-,ByM*d 3b*3vlsrC7Fiټ B$̺byOрʏVݾ'!v82׿50%xkucTP+Qɠ]Y,.`ҭA#.Y]PA|^?DZqy\y,[䡕Sj>Vsfnjv]3zIWo]s<@Kw*-Pzʑ;%S'&)3Z(2|IV馭apV6epCP"_˿vE?7K7E; 2 $ {n⏒ z%ĚȦG ]D ESEU zw|$\oy4>zIK#::uD'>dZϮ:Ri7VIxbMYp{9Mgeiy6ݻu9?g\~{NK/ j$cַ3Sw]i"I Dy{z4 `VGqXfR; ]=KX(}h|P \.f\E^8c]OXySR@;bEEĂsUA&PIqEVF V@&8 `L8vG hWoΥ;ç>ŅœzPj\ ܁o}?k>O]J}}"Jи %wf6gP6}`ѥ+T.6ѻӫ+9Q9ebyqÄIٸEŃ램LlvT䳮PjUPnst CwZضEF{wؽ F7zO{^1*Paɛbnȩ n2ETWH0p_;/}N2`aD*`tqh >F_j..nKw@qn@z,q5 ?l'**a,,0~k#_wݵڛmltX+tGcRO~#o~kGqԥK^)[#m^-ηJ;bz5P1ap6f.AmemObx;/]2 OqɕڶrsNW+84*RCD24FS]}k>` &҄,FkO}' ۡ|b_.`hC-Vs#.w왠1?,-ĭmMVhԣE)-xqoV)mr|&|C鋕c|kM.,{ngyp' g~9wYg]~gq\Fe3t2_ 7} 4YJP"byHm"B5b6< rW(;(ћA7NVy*wj 7 Tmfq| yusDl*DJ"?DtAXf&p csϟ?$LQz'>fol>_V~u$BB\_)sVr2N7{s]DwW: \ p/D#? #'r`޿18x+~Oy o^~>ttn׮f(lqUsZNb߿y ];ksѢ5BK7ZzTv7~k{bs6:l%`j)ߗK#Ftȕ#'|g?Y>ܚ Oh/_UoN?o|pؾ3N>TpV7v-~`{Tse9鍴=Dh?ZOm~ߋׇ3Gp܋pg;xo|֫(C Y(y{,^e~{Z g`T5ĉqN%I脏P0a Rc.2;'XT|;~ş{YCx8:}|}lVfp&2Z^'UB*25C]{]_Զo_ueiռP? O4!~(|-?">{C/W Q? ^F85 WbET{gJi 8"S}J{2:w;$o8.ʡzc<^XZCtrVit ّD1 ѡ |6Zݦ?˴QڒoS'ۯjsCMhڮb/}NJR]++7IobgQҐ˒>Цu}.+Wyvr5JYwNbL\n=T!&0J5C@e mh5/}fԋ/"`kV`J559<3T.xv G>V 2HFTBev ٛ* #O) (0OTljoM6Fw-r?k6r!0ܩ̣uǤ b$ ;0Lthm!J=iI2|C<4!C]^+kHlEZ?#,50()uSSMj;[x-b%)֓":@^9Njx[)丘1(4Qw6,m:z\2ҲFa9p 7"J [{'_?㩓vbAʐ Dkb #0bǦӄ2UԂC vpXr.[@C*oІP$C5}P ònC'uFi6g ݁ԋ2P:# iv3`5Vu74L8mRV5Ԥev#(;߈ tJ3M@IO<>'̺Ҟ/g5 p{rJ\ $ʔs| F=qTxY0B̒1RRƆ$mS(|L٘*c-w[|vAѢ:|?SUixJ.CӨYz}dh H- ԏ24}.K.F#m6_jUQ3MWV"J ϔAcHŕ2+ J*Sѡ:#֟X )e:bPQ^$ݭ/oo#w bnfw0$@[{SxIWGEZ; CVZLx2/|q Y$+18-C-H"R#RӪ.ڣw"^G|:=6푇ȅZ4&pp eS'SzO|c;bBD_qgQ}\ϋJgR]$^Y& qMgp|@=C)^GKm=J2"n"JЈC# 7F싞Uq}3zx-W}wt?v[3%YfJQ41JJJCڡI,1,y ~=)CCs :CA 8+q!LDfJ+eR7*MDpJhֵKU@՘Q\1b8܁VFkkX9wA6uDѽW}ÎEk9[TQa0mD=^mE~r4s!p` J|z*=)rZ~"zǨ*`bL(pAd1".?Ű!~s_T9h\XCEؖ!* [ H0.q݋^@PjjzW6]bf"UВ$U4X j\hO!}f%ed&?bZj{#EhL766xhNy)}Acn…xQn$g}{^h'hVj0ÄnO͊;7 F@BQy'J2m@l2 (0/NnlT f8O,n^mV+)J R'_D'NgGD劫 c:+J iSt@q^|k+1cy@c" W#=qtYlkK讜wwu8t=X/^?muϷb+%9Z&=EQ}(]}F쒉Jr,Y.MF#GzYzMP`ލ}Pť,Sd3bY7zOr*sS*hFrDuYL&DŽtO{#k t/Qy1A !b]@6IL#O7'x!'Nڏ2)ُˋjw9*3(.Re[YkgM!.{\n?u D5ŧݰf{J4Wڥ֌[tu>?u 2؉xAG$/@i ANhatЁذܮ ٶA/8Qj<+nq@Rj"\#@G=FM/@ hf ha7̀arKTQt2 aA2kS U3z.@`iUۏ;ERד bBǏ?\WWK{[?ohFͰ/uhA@eT>d}蘄Xz^|GTeс۶o?$?tBv{e|0 ]K GYټ?ӥO.6k{ﺿaxqMG;ujxcvnM9 ioNpU6"4ȰxHD$qm2-rr$aY/בV<ɴRFr-9FN>IUEI nm(lc1Y_Zgm]vsT;&=]> fU=xs'T:tg oշ5D}0nQ`? S0M _ͤJ =բFl _~YN2 ЀB5_Z-.>X꾘CˈS֦O/h _i83MflP#۵ѰZq+-`cT1ʭԭ냨7`phJTk2] "S~t4ӱCo_#w'Ràn}#^CàcL6}%3| uohtp>2-$Fy!(w0U=r3ZKjGQ4ި`u ZWkLHǡÐp[KUr -2&Tϋu \R1H0!гV!/|fw~BS3%])-bVAOKiQ{8L|駕<#j<$ȹ1JWqsα*,~ǹ?VAiCځ{@J' Ka[S*Z'BO:RuxWtPfqNCiVtIp(}G /+-(pB;ƴV2>~s GG f$(ק^W$"bdW^j F`(S`&V*$"&v95@7(Uʬ"zjՙ|f[SkZ_YzUP'([ @~m'\k2G-׶msZ`=E:J2u-ѰX/%gh f~W(HukmɅkU?mfst4ƥ% |K,DْZ*"OkjX6?{څnGcT9vTQH `۷^M^`<\`a[֛ Y,q8gG3ܴ)FÕBNu|ԫV5CoCZ7b*@+.?yݧ[ʲD`VY_ 8uшXMU,WX^>i'Bh fj ծnìfEF<8~X`WCqL Vf0qEq-IK^$鵤-R1GR+CB: $0 9ߡ~RBtMԨ8 9NVKH:9=}ޕW3RƲOg۬>ۅ"1`unxYpZgu$$ԑpZM*`- W`=:XHXzNE q`Q6$sD+HBM"*eGNش Et{/e\]Өk&M$;R;?_K>7~eOP8&;q*4xoIӥ]xmN[),x>r(32Wǝl9xtkʧ-j2d{noo`b+_ G ß+Vwacj*yyߺyߺ|=ࠎ@;z\:*`*uD+*^N<6t#7}kώԧBmWXQf'DBVr av٥(GwQyBs腥v7jGu7 Zӱњ\vt{  ݛ)fh-+wzuz3nCSZg]u2T<[`_4ucB8Zm1=6;7((SFvUwW~k/WR:aŝ('s5e-JUd‹PeGRF˩נ=f&.jfߗ-Dr/S'-x6]ʟN9{KWW:=͛C Zs^_:Xklm~*z/#jk֑4vu{bAkx>'wɳZ;+h} nQ1})ujSN?p.E?&BMI8 aL`qJx57ճt5_w&}KӨϡ+f[z$k;5nL0W~|l4ݏY;Y> hmӍ]{8 /bf\KV9-jfג;okeE,|)gZia3M2Zr&1z*880~/xX/}{|t:?ujqc9h>~/yԧH3/0B^}_w>W呧"!V*Ŕ|Rys?ʝ:6͋ s=t1Hua|hCZHqv e}B#HY`A m}_>rۦpIf'+:;̓ݵ_ʗ=E?\GB*K+Wt;JSZ 5i?̋lͤd'9,e l}f9|x8ըx_|WwWmϝ43-2>r7w S߾5=lkN^֊J0No{޿y-dv3BO~ٟ|'̷f{=Ӟ)P'B0zpd(z9g>?zPGk=BkyxN{e7zT̿n5DgQ:~CTb:]e7 "t6V~Ώ[x:ʸ5*k#T𚧟r}i^a8y $6혻={P^WĖZsI(s_'tQ@P頔"eDMQ\/F( c$=#IEfTwR:aT811|Q7sLjed%P,)KBSEjW#T"Eٔ}dHXnN0r X@*gF ,|ݷ|F֢=cg՚C +˦.Qܓ]@fɝ]̋8 ɕ*"ɥժV x~% S{`TB.>fm)z˫tv8PJAb,Z[5ˇ i+w9"GDRkwqAg$Ne3*(wHDRƠNmc@ >2D)Md8}5ZThvL'PQudA2):^|؟t3Z䱯k|Q'Uk4Z{vw/xOih^F9 -1K#tXu,MQ[?[/*X{<U& ޲(EBʏ{lBx2q* 9AB'dӐҋ ¬OU1>~L'|H?C5ǻ8̷5X/|\Q΁f^lAJ"s 8D@Cb(H-W8_@C2:sX:~0uVqFcʘa&t`*Zl.TDDH(uG5fTd2f.Ҙq߂sωqROzujlAYzjK.uՠXPC\EmU{ڠXXuQG2-txDH2ӻhױr I("ߣbjnM>< *e1490f"-5d_ %A'CL$ܲu%YgJO[ וT*!\/MUO+R87u~]D#Jb'0YSHGtH &wac f^B<&$X!Hƚ~z-r~Ш0a/a08{$9tRu*l/TVf߅YT(kr88 #b  i|@< \)Ъ w4ZzcsS<~HI2R `|Jq⤚n)t n&` sQ>!3}ocm~8AL&yRW\5~3!*sF"jW p.2}2wMx.qnw>q İ<{.e ӡ!(7|n5A#t~?0u R !2yd>4E3& DUt4Kc),W"TYKjr. o-0vȳ t67y'>Lq!Ȃ^r sH'駜ugcW3ҤmgRmDtiD)Maa2x3!-aZx .4쩚]+T)I+PNNoS6m# 8M>HTzD!S`I$H C> t ,4+uX,2bX2D,U$h<@OЃOؘ ±10yz~^hL 9D9IAT0Nڐng  R92oؔL)s :?#i.{_Wl{m6Elsg HA^ 탷knR.}9?s3Wt2" v/(zJ]N':3j7u04llE%H@FqC5 5!(1k:\0Xe{ :U2)v? AMŽ?a[~#Jc,NDesvbiPv o`xGX LǸ)px6"w (w)2Qqt;u- 2̏zO+^yndWѤ"CP atF=ޮO;[{g-ӗb'g32fAقDK삭ߍ^w Aw>:RIן+ڪu8ƽly.wJ* S)WWL:.\x]|8 LgY*z5-@P pD|O@YnJjݳķ8Xu˞!:; !cInrN;FbDWwZATKT >**Jl@*P߳wI\ *8?H!:z!gۯ=*8`^QJE޹S~\ .E'JD/+4%.WRR&}m؀xlt kYx_z?1:ogix7o' Aʔ%_3Ȋ")pn7dD0 Auʹ #0,No,4pШ㞩 Ykps!1D]Q"-&`a*eF ->!YUIf(dWymIEcz;e<dև*i5&h/ %'`4J'!{A2}GL$"D"K\NLKx.ī~6 xԂHK}gH%ɩi!;K!B@&ʷ]L 4,'J<]'yH~}DA*|Dxir?'ŻP`3dBI0N@Ad`qXg[}.7FT~/f65ǰ4j)Zdl9 #]o] ܨiY?_V?EǿgQ^'q؉QY.#|װ(\* DžJ\zE*0 pi홞rQ`_bߊ&1*{XNEAaa}$G 8)o}J δQ\ '@UZY~rˈdT<H&OH;'ʠʥp-Z,0HU6% (TPxu!=IKkCO(Y#ffd3"13r1pWysY~ Z9a^N= c-a[?6moSYȒz8 28=ġ 8H>Lٯ-Cg0 O&O0Jqy%Y,Ai&T\E~~=R%X'͎FDPS/D{o#5v[Y 烓OlW^mDO)4UF@FHĠ"_ƽ}.wVAu*~]F32QҌ(p|h ưB(6fEF ld\\W*<4JbLB5d5OAYF\LT/zÃJ7΅C1:(vLha{LBD=\;"6hfEJDĸk/x AaV7\f=h3!2]hxt6b''c%oe˙Lj}>מd]O vb|&=K*1nIFÄ].O?ʠ->9KPgE/vX`3e!X ܐiВ` W(q8ܳǻ޴ji>Ϳ0хAm@kxH0vId@9H0Ca"r jH#zW7Y-NޛcS Bc%*1wRdlIB&wiO@`k&_GYoQK&~يOW3sd Ibs@xR'+^pFeyO!kGn膈7(9'(: <*@<C$ (IʀC/\,)sar8^$H &˭ 8C5;~[jYpV rI=.y{*yxj||pXBvɑrLm8d4-҇$v׾wacN¶/s [Y$,A^ů1ljW!4DJJ{Zqq2PE7^6~ <Ϊ ^& ?BXs3x|r@x~Ku=m*PkStt(#&%qq!$S$tWD(Rl7 ZEsSdz H3D cĀUkI-#ղ`0eU(]_5seo_I`RyeLyr2psK KGI]DF`uT"ĺ;ñӅ,t]f "MSo}[;zg*93;ڶ/{z%(@V^DuTr@: &zS V͞nhuDUj'aI~pN>mqae" <#:zEÖ r~}0@CR9Pv.3DpODA]BڱS ̋i;::gQ?{5;X あc)OOk9lV/jۂʧӒԆ0;Rf[gYZP(YhJ(֑C-/0z,[K lmd.,X^Bm33S-6 H$T,ª"=FT#P\HHbHږY &s :W߀j,6ț oBuF_tmb2`pQuU(H`tY\y%Edk'̴Õ VAtnr[=.2^8*AX(MLD6<4vjN~{pt_}b=)\G‹~[g ݡ6Mj UzC|j7Rj q2`5 Z*]jH&e7s|tTr$e[/I[Yy :+EE[d3o\ж%Pd)(&hebaS.>T@pnjV5LĒ ( %J6(<QbM9.x|H^(cvrմ #PCz RSؿK}2 q~ʿᕶ-a[Eocqz/Ү^os_]?NZ6"&LuT(tz"a~quj4EHC S aD }R,dv8;  1] $zbTL`,ribzceAM! +-TnI`t۹TI R p=傪WEb*x=EH|R=/y)}ej=(W)4WԌo58!p إD,R^iM$%~ %[^%9Snc,ӕY~헪$sfHuү?wyzivJS/}v 2D݉Vv 6JqRVɩ XW&;rr+W?K;=uh8W@ 9-$>{Xo6.~[*g]էnG%*zCUx#w'`&.FCoҟ_^Y.֑[NS4x C: H"4r72\JIUozP%zh*")U4M>QK '('5GI[vJb^BZ+[jIVJq:cj% I۞m5lC3TM ]"Ug.H4 ԅTM&0^mEt6Fp=lAd g۪'j d%FOdG73N}{s ~l.7cI6}<GArlX \trHJHP?r+79r$ٚ*6CQ!V eՍup ufSJQ*9$!ffqi+2VګqgO;!霐OwD+£3=ZocW:+R\WW_oT z0sgOUɀf[mḻkKG@ik&: 8^ RxCd&ؼDAj|0^8UUND8mEaDk=٠1ZLG額FV; T8nB#na' .C}/{:,Z&hq~֩{xɍ#kF@ aIBk Ӌ;W;uI*!]= P,-We"B@^QGG38 HTz RN1D2=&ݘzx GzP ԉ1+գ8r ,d~5fKE|*{V*#GZ=W~V`iuNc $>%0}VK5bbb~L"Lo2sf4m{cz'RC>'[l][ 0)F bKDNx# +RH[ ڽက\QDv.CWԥKTsp!dPaz6^sG˟֨Kg%݅JSldlKhaW?}ړ_#騹0x4sx߻x$SnNnh .n`L۫U夅v|TKw?7Tw1G?d?_?w3ݵ1% 7`k󶋼mXPF #ۄVA*|yc-bDc^wsWVL~:?z羴q8,  [G$UEB$.Ct Zȿ5Wk>۽cvpG n?_C{V - ~,لJ8k*X xN:SGXϧO8I -:t3Xc(F~C#c:lD5Hv9er Vw!T jIua'tA(#ΑKֳi?(}BɲҗzmCc?47+]?O w.eH$;$l S{wٌyȶpמߣ:xU~@gI[7^>T=z޵6~m#(xQig"c` lp * BV40@-0_ff$H'XNz7=PqG#*bbӂ II!TPuk%anJYe, 顴YhKm˽`wJZb n[a"dڀ*qmtU=$C~}@eT*XIX{!\ +ń&?.R0 RJP@`P3;sZMs.")] ڋ45,mK¸+nƧtޯ ;dZ[W~|9[C5뼦C#e[h?2JV 0v9 ~wDdkLf/uhXUoͦjSLZuD&/pJ;UCO6[tw6U!H4Kpj\?]]m@ \PGG+bjE9_޻{'>DfMZ>ךn)N2d2W=řM7Q yᗱ_ʕHG E!n髑2ntqƲ=\3޺h0,Z1*| Xht%kqϔ{k휼եC(VYm]!'fI_{߫#^BD:;Rnq7_wLZ%1L␔d#$%|CGE}Cbt :UƲPl%]?מg^{y?,gC/aiZ| *=bhE958Ӈy^Z0e7$6nY_tfOT)'PFԪPE\zTK|VKj 2Fjb(t> Cy$$/J,",NKnaF ^\2 B5`f4XcT0ӪMU{g&iYj骮aPpFQ`@whL^CԸG(u˓{crpG7H( Ptea}yn ПE[SWrO?9ئяεҷ cܙ?֣E !6/妟%|L\ecSI$6cWlb~ӠX vgdAՂ馚xq梹ofhO>o4DS$xsp׃5z.಍➉q̞xH\}w\fZarݭ.zJ1>Q DDN* 6Nb Fs'+hGҳ4Nwh];6wyg]g[ŕWUYQYeɢH+ t5̬@[t!_uE #Bӆ͊2H 9yC,x-05UNbp2agk4#ZTٟg:4SSˬ3zD1:F#k`2B[VV -sq\.f>hӣC 3h_$pqJBu1΋RrIX_Qq?Џםr[8[J|(l·{nmQFLE4y sFו$g >:w']))NxbPҖyuB6ԫ 4ho)*.P #X-?tbm18kiHQo┚ծl%35ǂ=uܬg[äZʃҩիW_ ^l-c*x R.ZBQoc7Ld' 7~_"̭^[^:4-rn*~W=b)Qlqi~;؂tqv#bo HN9]y-٘GXUz4|nl&SGn-^㫾 s~o> >8b fTRt4k5K е홭'KW}sׇ1P=~ۯvw4[-ײЫǦjO.52MqpbЅҐ嬄c5'PD5 $$%}@ȸ⺲^ਨ+1\:.B0T'FΝ/@%:9Ν?r 2r^,1{t dp\i;ҝb9/%*یo03m]]sh8WZ !dg׍&Ƌ333nSh▟}oN[Nh8_ʍ"b'P6d wgzz AȾo_U g Z'3 H% " WD[m: 8 ysUHxfd8 P h;A90jIYLЉC @~^0rǏG⽱ldͨnԟ,hybc nr+z fUZ&/wqW=-JPa4NX-@rXQkq F4x~-PLAjnI*#ܪV##3K>{q^4y&O^;4wG[wX@\ L - R1禯_zs3W?_rg@{ّKtYw?nƺW3 '5FgdKC2ZW=y-P$r[$b4\/ڀK+a$>0/d({yXD-GNtuDnCPp}~[UG9Q1 ݅+0f>߀j;um45TLrbhJ*xr_h+/v7<\$]:0}vq?T&dF2u#745o|?ۭTfZ56pS^I'juAm][7ٲ{`v2%5xaeڂ 30ęcj-E1zW!ZPQ`j!E6Opkl%Ċ3#p6 |%X&z^&׎'BKg@w'&`9]G0 _%X OF_CxXiۙ1ucwO+Z ku6 i,#h0,˓cҕ۾ցiP؍h3_O[H.Mvϔv_3X[[WOylTex'L€*t[- v3 gLyose)a4lDQƔ6 5NS$ hI&ٴ-}\[W#ېCNq9۲[vY 2=R&^צY-°RzJmD,${R>Xi.IJVf ?i PS|6%LOJ_;47L!F%0W֍r+m+00xid i&K()"d nFMosdn{R2ԅE0rkƣ#5Y7v{B.;Lwbrz,]4 'ÑP#6?9(rHL):4ŹE.'-3K3sG'( s5r6缾 ݾew۳ U:wG"o4bm"$\EQ熬ـ7-wtB;"+[h~DעcG+N!!^e ߡyq|uLJ0[w0uo#:6+"jP~DPP@5hUgS\f #c&`P'Q%29veّh&ukw?TYתroEv{颸E n|?bPg9w*&ыˌz-> xLA~C.ҥMǍ+4 z.ĭc]U] h?8zNJ<[3{G0/ ]^8|~El8_:YWuXFNqA!<GE/$ð̨XYD4dIOҨ!ZnP hʎ؁ .,$$e2 QpqV[+BۥP\- +\wm{Xa N9Ifh~fw0K8Y8wß}8u԰>ę^W8C{,~资);2hq؞DwцoBY.d˂O2yTq QYI4y^IB0 1,gKA^8jC6LfM7ҋmC 0x|No{E#+[[ -񹖠Ke|L0Df.`ãг%>/Aij1 ]YA-:<.`}8XUphqy%Yyqp؃xfx]mP_at#ȯS?1H%B#T"1QuME'ΕHJC=oz+Hart&;ӂ(@0;) t]bqA<4 ỷc .u9r %9hrAc(@;3msi[}SUGWkGկ}b5T`[ֵH]ΐi@Ą**~?ؑl3jL[G RGbz?Qy!ї6 }cd!G#kA5XMUGL0â+Hgtn;y1pD+V=,GiY>ET0dnO%WXp 6BI-ЅTAMv tzm34$8k$ÎK.ΐY\  nz;#Cͅ IGlE{߂{hYEpU+GQ4ЩkMfu,HQF#3T1Q$4Hiovˍ3ty^ Jr(Btڋ xJpDe˱@ˏ\t؁2,FHC#4S/1`ui%{}\bpD|Xwt)hpqT ;.sZڂPgXDaqL6X4sn:G qɄ~2uL(-1yH3i1"DQX8BbTZBIY4܃aqK B4۩5Qba\t[1/nnVD!)3w̑:E9prPZmk;84U75+a<>OizT[QDH&.VIIg xiK֓vG-V$EGp^@f|g61xćlnrӊu@G]2AP i=svnDVwwV_>PD.3YΚa|ǜ&lL H=yr/hFP˝״ ?8d\pd=Rlfb̡&ByKyIa ҮnJ,.&_ —%B`adf,@eM! ^ ߝJ4^[hK `Rٺs! UOC=G{DK >}{Mkgg:;~ӷPCJ;V.ݻ[:8"zg<)O?wi'0Gf02q$d0є~Ѵ/ЯYRw c쟛؟!ͣ+\%48Jf)n9Wq @wMa"br :6ȁŠ/e 4% 5VgNjrb4k[`oLrSA(t;9JJk!3T>XB'?lyu)$Li}~0\}ۦ#.CmZi_D,=9"K5h\49tiU_7M#VI(BqZ`|.֣>ӯ3غqR)[Gs;޵~t~%9~}.m}3g=f|ݚCDE94:6^ؿO\z70zܽEdsʅg50N'2ZVaTa O%"e֮JHF:DJPcd J_܎1[5L/wCTD (%R98$im pKJ4rP;гeoZj|ʷ7C2yOGC QRPk_ %#0Q5`>C1?֛bm=l}V 6JIݱGvJ~NY(sUG˵rq^r-?HJ߽c?(:>\Fڰhfb YYJ92r4q;nq-#Kw\#;댷Ϗ)dÚV{coCx9ˁ$EjRȡ_dR)E)J:#/[%h$xw\,f;Ҙ\ &>/7ܖ=iF` Ǡ9N:{81ݷ'F .V&tY0ue P6 seX15?X}Ix<+O0Wd񓟼Se:h7C3_?{6>JMTidYl,糺=Wlq> oqB`es5 oGJ?t_7Hi_ wU8F 9HRi%\t' brH60Ģ[2i0.!|}?æഺ G ؓjDžNsgW;'W''5Yxm3X/4OF}*M ߉HSi`VzC+tݛ;ۿ]l{%l>gD~L6U$K |UŤ5]9/;j;E-߯v e=@Ф=DNku1m l| ҺeH!EFc!^sSV_FS}0)ʸ EC$@b6lI ޲kE 8Fԫb_K*VU M܌hg*$CIL.kvH_2 :Gт!Vm*VVKF O<Ul:&F10&+ =[]dJÏ#Gc[5N%ʽ]"c9j+|@5qiёQ!x˥#4N'7>YK۪U%t_81z-ƭaҮxI#=比U舔" _1b"h.QGGsQ448 iv^U)-|X-HRS#lz&Ç܉9t`@A4VoMW+p##,b|YgFB.X*XE f::@e"fX)qp!I$cp2HΏR1|s֏3lMF&sBViJ!DU˅+Se\oe\ݎ+D,Vgg@K$@;{d ?Q()1"uy]wt覬yoH!91ݸ>]hɱ\b,x. 3=>210^?''k'Bx]3ÄyQ_+GV>[D28Վh<2nYŪԴ &^J  dF&rw~؅1NxIǭ2)D.mHw &: c4# cRnIfSS]D`Ad'6\PlCDvl^iN"a#ѩnEL g@Ɠoh}kI 7r,Vcl.[UG@i=bH7FbO0f42_]X-oͿd%O ZX`;`jZo;*"5>lr\3GJF5S-u8`ٻO]=HIR^X(TfѢ 3J"ܡr5IGދ^~_ )K~bx2x.~jT#Zoh5baRh7cPr" wJ\.w?]+Qz$/7[_@IKR3=:޷ dh,}; ߽ޓS"vv}Ӟ~S#}3m[ũNiAغGɻ9(^GŮCݹЈq*92>@ A j#r?GgS8mh x[e0g[韝D0KG(GoS,v|ERizw7>sEMon =_VqG2^ WJը.&\`1wZ[#8Xq4E 3) V[nc ]jmL3ǟ*ChNDmWxg*]l"㝰yrM"~Epxzd#@A^l.Uq `{/XP:UlثڈB;UǑɬ'lG" 6s } ħwD,k<VYYrAOI7eKr*zyvfXybcxE/ÓxZ(Xݎ+ '&"uV%^(GbcSN2Y`" YHz9u$7?"BW%^㘳VU3aMdG1tj؛(@L%^n.DPa/!8ծB~K$Z#DlB7 7 )- ύgN=wFNx>M9p߼NYv3jA4kʄ=\WB"cOkF ߇%8Z># :?]:Ink's-ص,굪[Iqʩf'C5%%3lb|[DO>5j,nYC.OCŏY?$!~bMS.hu߼割knQJ+^ott!I,72<<< ae%M h*-ϏCNs}㤓u+s]_B~r8n&ӫ'w|roo@h<3Yo~}$3^q:K [ QB# :kHXYLI@ǜRDXm*+pz?,D<[o;|{dN-iNo}#Bġi4fzͪb ,o/CFXXnd90ܠd94Wmţ;ǘ+4Fk"CD;gtaf>;&44`j?z/awȠ{ԝmqj҈nS돧}}2ͯ|Kb2ڻڳk7mCOH_ʚjGcvH[JÈd^"{=9?+wjQ}  ]Xj]^k2Ӯ7~5m>VVpA`.WG$Hq,)Hr @ UiVI&GW^k*OV[&ۉȉzE8gnP/yb} }vћ߾l={g%M^:Q: L!ytqȅTƱe%ƥT##fjݝnԡQx7];woo@<;Rv*-N90 Lw`vܾgZr7;A۶m3=} v*w?c ƦI-ʖ`R8B({hP|$\v7vJ%0`la~ѱB,Il=k睓}lհ*P>ՒSuWjXWXu*[C-(< Q)Rx~JK 揰)"\;Zh#BjdC7Nu %@xD\np'4Y+R`'6FߧӜ*RXH˗'WhSRjv@TˁGt9RIENDB`(Voorstel structuur afdeling Registratieane Normal.dotdlh2Microsoft Office Word@F#@*@#@#~ o՜.+,D՜.+,T hp|  dg3DocumentSummaryInformation8 , CompObj6qB\' (Voorstel structuur afdeling Registratie Titre(X` _PID_HLINKS_NewReviewCycleAd6=https://portal.health.fgov.be/portal/page?_pageid=56,512448&_dad=portal&_schema=PORTAL&ITEM_ID=9088418&SITE_ID=56&PAGE_ID=513082&ISPORTLET=true&P_SECURITY=ON/xSVhttp://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.doc/xmailto:fin@fagg-afmps.be/j:https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/GENEESMIDDELEN1_MENU/HUMAANGEBRUIK1_MENU/REGISTRATIE17_MENU/TOLERANCEZERO9_HIDE/TOLERANCEZERO9_DOCS/ROAD-MAP-2007-08_0.DOC/x mailto:fin@fagg-afmps.be/j: https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/GENEESMIDDELEN1_MENU/HUMAANGEBRUIK1_MENU/REGISTRATIE17_MENU/TOLERANCEZERO9_HIDE/TOLERANCEZERO9_DOCS/ROAD-MAP-2007-08_0.DOC/?Smailto:varana@fagg-afmps.be/?Smailto:varana@fagg-afmps.be/xSVhttp://www.fagg-afmps.be/en/binaries/CHECKLIST-closing-EN-2008-06-04_tcm292-26608.doc/  FDocument Microsoft Office Word MSWordDocWord.Document.89q      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrs$@@@ NormalCJ_HaJmH sH tH 6@6 Titre 1$@&5\6@6 Titre 2$@&6]R@R Titre 3$<@&5CJOJQJ\^JaJ:A@: Police par dfautZiZ Tableau Normal :V 44 la 2k2 Aucune liste 8>@8 Titre$a$ >*mHsH<J@< Sous-titre >*mHsH@ @@ Pied de page  !4)@!4 Numro de page6@26 En-tte  !,, TM 1mH sH JRJ Note de bas de pageCJaJJ&aJ Appel note de bas de p.H*FrF  BallontekstCJOJQJ^JaJvC@v Retrait corps de texte $0xx^`0a$CJaJmH sH nP@n Corps de texte 2$r1$^`ra$CJOJQJaJmH sH PB@P Corps de texte56OJQJ\]^JNN Texte de bullesCJOJQJ^JaJVOV Bullets & FxxCJOJQJ^JaJhtHZ^@Z Normal (Web)dd[$\$OJPJQJ^JmH sH BU@B Lien hypertexte >*B*ph\O\ K>p Table Heading xx5CJOJQJ\aJmHsHJ'@J 3EMarque de commentaireCJaJ:@: "3E Commentaire!CJaJ8O!8 !3E Car Car_HmH sH tH NV@1N rdLien hypertexte suivi >*B* ph+ + ;DFX|* w T B,00000000000000000000(0(00;0;0;0;0;0;0;0;0;0;0; 0; 0;$ 0;$ 0;0; 0;0;0;0; 0;' 0;' 0;' 0;0 ;DFX|7* w T BJp{ s"#%K&k&;'f((),-///Z0D1244 44444445526#8Y89a::;O;`;a;{;|;}; <<<<=>? ?'?(??@@@AvAACDDDHDID0EEE#FrFFG;GG H HHHEJ^JKNL_L`LtLuL{M|MMNNOO/PWQT3UqVVVKWgW YYZ:^#`nabbc e=eefh|iiUjZkll;m? ?'?(??@@@AvAACDDDHDID0EEE#FrFFG;GG H HHHEJ^JKNL_L`LtLuL{M|MMNNOO/PWQT3UqVVVKWgW YYZ:^#`nabbc e=eefh|iiUjZkll;m !28C G t x [h`m=G# "+8A`t2@vl"p"9)E)[)d)L*X*o*x*,,--00444466O8X8h8q8~8888888899/9>9T9c9x9999O;V;e;x;};;; <<==='=0=O=c=========>">B>Z>>>0?;?=?@7ACAAAAAAAA B2B?BQB\BrBBBBBBBC^CiCQD\D^DEyF~FFFFF3G8GHHnJwJJJJJJJKK)K8KNK]KrKKKK0P5P/S8SSSUUVV6V:VZWfWvWWWWWWWWW XX'X=XLXbXqXXXXXZZ` `gbmb_ckcee888;M;<<(??AAID/EIIKIfJlJaLhL>MJMMMZOeOOOIRPRWWZ\`\ee iiii`lblss;t(?DDEJ^JNL`LaLuLt 2o !b"q\Nu/uC)WGd\£rkLbk%P (]_p""E0M"4>&z@. 'k^A)` vt)?ΟYE-4 Gt o 7g- (hz n"q G<_p"!0xEqAXS' K?q{fiu/u>&vt)k%. 'Ff HP8 lxvYE-_D \{ qyS@ ^A)(s,.tIM"J I-QHZGd 0? MM,,         -H        y        K%<td<        ģ<'         p        #Rdpr%        ^A                 zjK        2         `                 nzjK        T        zjK                 ւL        h:#VY4        D)Ʃ        \Z                 A* 0 Sr(M6:.c$S ,eQnROn_sStay(*< Hoot  J uN [ 8F=Zu FyotoG(f p"n#Xt%x(+h,a- _./7*/10- 1$1%1*34J24U)5)m6#9c:i;$<G=[=.>#&B06DDGbK2WMZNeOt S] S!XSmTtUZe7Z1]/^j^Icrdef2j4l mh*mjoK>pAqKy}z8{{q|v}_~{@~}Hcx%pD[>9Sf&-r1+Vr;5%pJXoj{8 W-t)/i-8,9.=3EjMh)l+*_II|PPkT&Lao w;b\f$$LgVYy;ge8yL@b5&hiVKg Fz.0-dh[o,_V@   4HJ+@P@@Unknown Gz Times New Roman5Symbol3& z Arial5& zaTahomaABook AntiquaI& ??Arial Unicode MS?5 z Courier New;Wingdings?Wingdings 3"1h܆܆܆~ oB~ oB!4d\\ 2qHX ?8{2'Voorstel structuur afdeling Registratieanedlh,                           ! " # $ % & ' ( ) * +